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Rare diseases are chronic and debilitating and while individually they affect less than 1 
in 2,000 people, collectively they have a huge impact affect around 1.8 million 
Australians. Approximately 80% of these have a genetic origin, however only 30% of 
patients receive a formal molecular diagnosis. RASopathies are a group of rare disease 
that are caused by a mutations in the genes involved in the RAS-MAPK pathway, the 
most common of which is Noonan syndrome, which is characterised by heart defects, 
short stature, chest deformities, and specific craniofacial features. This study focuses 
on the effects of a novel c.173C>T (p.Thr58Ile) mutation, found in the NRAS gene of a 
patient diagnosed with Noonan-like syndrome, on the localisation and function of the 
NRAS protein. In doing so this study aimed to validate the role of mutations in the 
patient’s disease and provide information toward the creation of an experimental 
pipeline for the validation of other rare variants. 
 
Methods:  
U87-MG cells were transiently transfected with the NRAS constructs tagged with 
GFP2, and stained with specific antibody markers to determine localisation of the 
proteins using confocal microscopy. Functional studies included an Annexin V 
apoptosis assay, using flow cytometry to detect and quantify levels of apoptosis in 
transfected and untransfected populations, and the prediction of conserved domains 






Results and Conclusions:  
Preliminary results from this study suggest that there is a difference between the 
localisation and function of the mutant and wild type proteins. The mutant protein 
was seen to co-localise with the Golgi apparatus as expected if the mutant protein was 
constitutively active. However the mutant protein was also observed to co-localise 
with the markers for the plasma membrane, nucleus and endoplasmic reticulum 
indicating that the mutation affects more than just the activation of the protein.  
 
An increase in apoptosis observed in NRASMUT transfected population, in comparison 
to both the wild type and untransfected populations, indicates that the mutation is 
engaging the pro-apoptotic function of NRAS associated with an increased activation 
of the RAS–RAF–MAPKK–MAPK pathway. Bioinformatic analyses identified that the 
mutation is location within a number of motifs involved in the binding of GTP and thus 
the activation and inactivation of NRAS, directing further studies toward the 
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1 LITERATURE REVIEW 
1.1 Rare Diseases 
Diseases can be devastating and are often a lifelong concern, rare diseases in 
particular are one of the most difficult types of diseases to diagnose and manage due 
to their rare nature, heterogeneity, and often unknown cause. In the United Kingdom 
a rare disease is defined as a debilitating or chronic disease that affects less than 1 in 
2,000 people,1 this is also the definition adopted by Australia, however many rare 
diseases are much more uncommon.2 Despite being individually infrequent there are 
between 5,000 and 8,000 different rare diseases meaning that when assessed 
collectively they affect around 8% of the population,1 this equates to approximately 
1.9 million Australians making them a serious health concern.3  
 
1.1.1 Diagnostic Odyssey  
More than 80% of rare diseases are believed to have a genetic origin.3 This origin can 
be the result of variations in the deoxyribonucleic acid (DNA) such as coding or splicing 
single nucleotide variants (SNVs), copy number variants (CNVs) and coding or splicing 
insertions and deletions (indels).4 Despite extensive research and numerous 
discoveries on the causes of genetic diseases via phenotypic diagnosis, up to half of 
children suffering from such diseases remain without a genetic based, or molecular, 
diagnosis4 and only approximately 30% have received an official clinical diagnosis. Of 
those that have a diagnosis approximately 30% waited five years for the diagnosis and 
in approximately 50% of cases the first diagnosis was wrong.5,6 
 
While some rare diseases are more easily diagnosed; for example those diseases that 
have a Mendelian inheritance pattern and are monogenic,7 others present a challenge 
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for diagnostic tools. The ability to diagnose these rare diseases is challenged by their 
infrequency and by their heterogeneity; as they often affect few individuals and 
families per disease7 and multiple mutations can cause a phenotypically similar set of 
diseases. This is further enhanced by the fact that these diseases are rare because the 
mutations causing them are under strong negative selection.7 This means that 
transmission to subsequent generations is infrequent, with mutations often being de 
novo in nature thus undiscoverable through non-sequence based techniques such as 
linkage analysis.7 The infrequency of these variants; which leads to underpowered 
analysis, and their other characteristics mean that it is often necessary to use 
sequencing to directly detect these mutations.7 
 
1.1.1.1 Sanger sequencing 
Sanger sequencing has been the main technique utilised for the molecular diagnosis of 
genetic diseases and is still the test used in clinical genetic testing to confirm a 
diagnosis.8 Sanger sequencing works by incorporating tagged di-deoxynucleotides to 
single stranded DNA one base at a time. These di-deoxynucleotides differ from natural 
nucleotides in two ways; they have a fluorescent tag so they can be visualised and 
they lack a hydroxyl group meaning that when they are incorporated into the DNA 
synthesis ceases and the fragment of DNA detaches from the synthesis complex. Using 
these di-deoxynucleotides the sequence is built up, small fragments of DNA at a time. 
These fragments are then ‘read’ on a gel or through capillary electrophoresis to get 
the final DNA sequence. While Sanger sequencing is exact and accurate it is limited to 
analysing a single segment of DNA at a time making it neither economical nor 
efficient.8 The limitations of Sanger sequencing make it inefficient for the diagnosis of 
rare diseases when multiple genes need to be sequenced, thus over the past decade, 
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there has been an increase in the use of next-generation sequencing (NGS) 
techniques.8 
 
1.1.1.2 Next Generation sequencing 
NGS is a sequencing platform that allows for the rapid sequencing of multiple genes in 
one reaction to a single nucleotide degree on the whole genome scale making NGS 
time and cost efficient.7-9 There are four main NGS techniques; pyrosequencing, Ion 
torrent semiconductor sequencing, sequencing by ligation (SOLiD) and sequencing by 
synthesis. The more commonly applied currently, is sequencing by synthesis which 
works on the same premise to Sanger sequencing, however all four 
di-deoxynucleotides, and no nucleotides, are added at the same time each with a 
different florescent tag. This technique, along with the other three NGS techniques, 
allow for multiple sequencing runs to happen simultaneously. Because of this 
advantage NGS has led to the identification of possible pathogenic mutations in 
multiple genes that are potentially associated with a disorder through whole genome 
(WGS) or whole exome sequencing (WES; sequencing the protein coding regions and 
their regulatory sequences).8,9  
 
The ability to more easily sequence a large portion of the genome, combined with its 
consistency and robustness, makes NGS an important tool in diagnosis.9 In particular 
one of the advantages of NGS is that there is no requirement for prior knowledge as 
the whole genome, the exome or a panel of genes can be sequenced rather than a 
specific target; this makes it the perfect tool to use to diagnose rare diseases when 
the genetic origin is unknown or when multiple different mutations could be causing 
the disease.10 NGS has also allowed for the expansion of phenotype-genotype 
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association studies.11,12 This is because NGS allows for the unbiased sequencing of a 
larger portion of the genome and the relatively inexpensive sequencing of genomes of 
both healthy and unhealthy individuals. This allows for mutations that would not 
previously have been sequenced to be identified and compared to healthy individuals 
thus linking to a particular phenotype.11,12  
 
Despite these advantages, WES and WGS remain primarily in the research diagnosis 
scene, they are still not often used in the clinical setting where Sanger sequencing is 
still the gold standard.13 NGS of a target panel of genes is however more frequently 
used in clinical diagnosis. The advantage of a targeted panel over WES and WGS is its 
increased speed of execution and reduced cost, while still retaining its robustness and 
reproducibility.9 A targeted panel also decreases the likelihood of incidental findings 
which is one of the major problems associated with WES and WGS.14  
 
1.1.1.3 Current diagnostic pipelines 
Following thorough phenotyping of each patient the current diagnostic pipeline for an 
individual with a rare genetic disease involves gene-by-gene diagnostic tests.5,13 
Sanger sequencing is most often used for this stage and is most helpful if the 
phenotype is highly suggestive of a specific causative mutation. However, in cases 
where no mutations are found in the suspected gene, other possible genes need to be 
tested, leading to a long and costly diagnosis.13  
 
In Western Australia the rare and undiagnosed diseases diagnostic service (RUDDS) 
was recently implemented within Genetic Services WA (GSWA).5 With this pipeline if 
no molecular diagnosis has been achieved after the use of single gene techniques then 
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WES data is generated allowing the analysis of multiple bioinformatically selected 
genes from the WES data5. A gene panel rather than the whole exome sequence is 
analysed currently to reduce the number of incidental findings.13 This pipeline 
currently give a diagnosis rate of approximately 30%.5 There are several studies both 
internationally: Finding Of Rare Disease Genes (FORGE),15 Deciphering Developmental 
Disorders (DDD),16 and locally such as the collaborative SeqNextGen project based at 
Telethon Kids Institute, that aim to increase this diagnostic rate by analysing the 
complete exome. International studies suggest that this should increase the diagnostic 
rate to between 45 and 50%.  
 
This honours project focuses on a single novel variant identified in the NRAS gene of a 
patient diagnosed with Noonan-like syndrome through the RUDDS service and 
attempts to validate the role of this variant in the disease.  
 
1.2 RASopathies 
One group of rare diseases are referred to as the RASopathies. RASopathies are 
caused by mutations in the RAS/mitogen-activated protein kinase (RAS/MAPK) 
pathway17,18 (Figure 1.1). RASopathies include Noonan Syndrome (OMIM# 163950), 
Costello syndrome (CS; OMIM# 218040), Cardio-facio-cutaneous syndrome (CFC; 
OMIM# 115150) and Noonan syndrome with multiple lentigines (NSML; 151100), each 
is associated with one or more components of the RAS/MAPK pathway. This diagram 
shows how mutations within more than one gene can be responsible for the same 
phenotype and mutations within the same gene can cause a number of different 
syndromes. One example of this is that mutations in KRAS can lead to CFC or Noonan 
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syndrome, and Noonan syndrome can be caused by mutations in a number of 
different genes (Figure 1.1). 
 
Figure 1.1: The RAS/MAPK pathway adapted from Rauen (2013).17. 
This pathway is involved in cell proliferation, differentiation, apoptosis and senescence17. The 
boxes and dashed lines indicate RASopathies and their associated genes respectively. These 
diseases include Noonan Syndrome, Costello syndrome (CS), Cardio-facio-cutaneous syndrome 
(CFC) and Noonan syndrome with multiple lentigines (NSML). Full gene names in Appendix I 
 
1.2.1 Noonan Syndrome  
Noonan syndrome while a rare disease, is the most common of the RASopathies.17,18 
There are ten different recognised phenotypes of Noonan syndrome which affect 
between 1 in 1,000 to 2,500 people. However, because of the range in severity of 
symptoms this is likely to be an underestimate of the true number of people living 






1.2.1.1 Characteristics of Noonan syndrome 
The ten phenotypes of Noonan syndrome share common clinical signs including heart 
defects, cognitive deficits, short stature, chest deformities such as pectus excavatum, 
pterygium colli or a webbed neck (Figure 1.2a) and specific craniofacial features.19-21 
These craniofacial features include low-set ears (Figure 1.2b), ocular ptosis or 
drooping of one or both eyelids (Figure 1.2c), hypertelorism or wide set eyes (Figure 
1.2d) and down-slanting palpebral fissures.21 These clinical signs however differ with 
age and decrease in severity between individuals, leading to mild cases often being 
overlooked.22 
Figure 1.2: Clinical signs of Noonan syndrome 
Including a) webbed/broad neck, b) low-set ears,20 c) ocular ptosis and d) hypertelorism. 




A study by Allanson (2010) attempted to define the specific phenotypic traits and link 
them to specific genotypes of Noonan.24 In this study the faces of 81 individuals with 
a: PTPN11, SOS1, RAF1 or KRAS mutation, were studied by two experts. It was 
determined that facial features alone were not sufficiently different between 
genotypes to allow for the patient’s genotype to be predicted from phenotype alone. 
The study did however, conclude that certain features such as face shape and hair 
type are suggestive of a particular genotype.24 
 
The phenotype of Noonan syndrome changes throughout development,25 in the 
newborn the most prominent features include hypertelorism, macrocephaly, a deeply 
grooved philtrum, low set ears and wispy hair. During childhood and into adolescence 
the face typically becomes more triangular with a wide brow and hair may become 
curly or woolly.24 During adolescence, as the neck lengthens, webbing becomes more 
pronounced.24 
 
1.2.1.2 Treatment and management of Noonan syndrome 
Noonan syndrome is most often ‘treated’ through the management of its symptoms. 
This can include early childhood surgery to correct ocular deformations such as 
strabismus and ptosis, as well as early evaluation and management of cardiac function 
and surgery depending on the severity.19 Growth and motor development are also 
assessed frequently and speech therapy and physiotherapy are commonly required.19 
By adulthood the majority individuals with Noonan syndrome are able to function 
normally in the adult world due to this early stage management and counselling.19 
This is further enhanced by the reduction of signs and symptoms with age.  
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1.2.1.3 Causes of Noonan syndrome 
Noonan syndrome has been associated with multiple different genes involved in the 
RAS/MAPK pathway, including the more frequently associated PTPN11 which accounts 
for 50% of cases and SOS1 (10-13%) as well as less frequent mutations in the KRAS 
(<5%), MAP2K1 (<2%), and NRAS (<1%) genes.18 The ten phenotypes of Noonan 
syndrome, while sharing common symptoms, are each associated with mutations in a 
particular gene. There are also multiple Noonan-like syndromes each differing slightly 
in morphology from Noonan syndrome. Each phenotype of Noonan syndrome, their 
mode of inheritance, and their associated gene are shown in Table 1.1.  
 
In general Noonan syndrome has an autosomal dominant inheritance pattern and, 
while de novo mutations are commonly the cause of Noonan, between 30%-75% of 
cases have an affected parent.19 The exception to this is Noonan syndrome 2 which 
has little known about it including its cause/s and is the term used for the phenotype 
of Noonan syndrome that is inherited in an autosomal recessive manner.26-28 
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Table 1.1: Noonan and Noonan-Like syndromes, their inheritance and associated 
genes (OMIM Database)29 
Name 














































Noonan syndrome-like disorder 




Noonan syndrome-like disorder 
with or without juvenile 












1.2.2 The RAS Family  
The RAS proteins, named for their role in forming rat sarcoma, are members of a large 
family of guanosine triphosphate (GTP) binding proteins and a major part of the RAS-
MAPK pathway (Figure 1.1). RAS has three isoforms; Neuroblastoma RAS viral 
oncogene homolog (NRAS), V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS) and V-HA-RAS Harvey rat sarcoma viral oncogene homolog (HRAS), which are 
universally expressed and are highly conserved with more than 90% sequence 
similarity.20,30 These isoforms differ only in a region of their N-terminal called the 
hypervariable region (HVR), which is involved in their function and localisation within 
the cell. Due to this HVR the three isoforms are functionally different and thus not 
redundant.30 
 
The RAS proteins work as molecular switches for signalling pathways including the 
RAF1/ERK, PI3K/AKT and RalGDS pathways (Figure 1.3).31,32 Through these pathways 
the RAS proteins have a role in the regulation of many cellular functions including cell 
growth, migration, survival, apoptosis and endocytosis (Figure 1.3).33 As shown in 
Figure 1.3 this is achieved through their intrinsic GTPase activity by cycling between 
their inactive guanosine diphosphate (GDP)-bound and active GTP-bound states.34 
This cycle is facilitated by guanine nucleotide exchange factors (GEFs) and GTPase 




Figure 1.3: Simplified RAS pathway 
Showing the activation of RAS through GTP binding and inactivation through hydrolysis of 
GDP mediated by RAS-GAP and RAS-GEF, as well as the pathways for which this 
activation/inactivation acts as a molecular switch. 
 
Due to their role in a large number of processes essential for survival and growth, 
mutations in the RAS proteins can cause serious and debilitating diseases including a 
large number of different cancers, such as carcinoma36,37 and hematologic 
malignancies,38 as well as RAS-associated autoimmune leukoproliferative disorder,39,40 
Noonan syndrome, CS41,42 and congenital melanocytic nevus syndrome.43 
 
1.2.2.1 Structure of the RAS isoforms 
The RAS genes are made up of six (HRAS and KRAS) or seven (NRAS) exons44, four of 
which code for the protein, shown in blue in Figure 1.4. The RAS proteins have four 
main regions, a P-loop which is involved in the binding of phosphates and two switch 
regions (SW I and SW II in Figure 1.4) which are responsible for the change in 
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conformation resulting from the activation or inactivation of the RAS proteins after 
binding/hydrolysis of GTP (Figure 1.4).20 As well as the HVR, which consists of the last 
23 (KRAS) or 24 (HRAS and NRAS) amino acids, this region is responsible for the 
subcellular localisation and function of the RAS proteins.30 
 
 
Figure 1.4: Diagram of NRAS structure modified from Cirstea et al. 201020  
a) organisation of the NRAS exons, with coding exons in blue and non-coding exons in grey. 
(b) The four main regions of the RAS proteins including the P-Loop, Switch I (SW I), Switch II 
(SW II) and the hypervariable region (HVR), as well as secondary structures 
 
The RAS proteins function as a molecular switch by cycling between their active GTP 
bound and inactive GDP bound states.20 In the active GTP-bound state the switch I and 
switch II motifs (Figure 1.4) undergo a conformational change that enables RAS to 
bind to effector proteins and activate them.20,45 This interaction is terminated by 
hydrolysis of GTP to GDP, which promotes a switch toward the inactive conformation 
of RAS.20 Mutations in any of these regions or in residues that would cause the 
disruption of any of these regions can cause serious diseases. For example, mutation 
in amino acids 12, 13, 59, 61, or 63, lead to impaired GTPase activity,46 and due to the 
importance of switch I in the binding of GAPs to RAS, mutations in this region could 
result in RAS remaining in its active state.47 
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1.2.2.2 Localisation of the RAS isoforms 
The RAS proteins are expressed in almost all tissue types with the exception of 
adipose tissue.48 Their expression is enhanced in the pancreas, cerebellum and lower 
in soft tissue.48 While within the cell, the RAS proteins have been observed in multiple 
subcellular compartments including the Golgi apparatus, plasma membrane, 
endoplasmic reticulum and the inner and outer membranes of mitochondria.30,34,49 
 
A study by Wolman et al. (2006) showed that NRAS has a relatively wide distribution 
being present on most cellular membrane containing organelles, with at least three 
distinct subcellular localisations: the plasma membrane, Golgi apparatus and 
mitochondria.34 This is supported in studies by Quatela and Philips (2006) which 
showed that there is a large amount of trafficking of HRAS and NRAS bi-directionally 
between the Golgi complex and the plasma membrane.49 Another study showed that 
tubular post-Golgi carriers transport a number of membranous proteins, including 
NRAS, from the trans-Golgi network (TGN) to the cell surface.50 
 
The subcellular distribution of the RAS isoforms has been suggested to be determined 
by their activation and, in turn, regulate their function.  This came to light when 
studies found that, while active HRAS is associated with both the Golgi apparatus and 
the endoplasmic reticulum , only active HRAS associated with the endoplasmic 
reticulum is able to activate the RAF1–ERK pathway.51 Another example of function 
differing between subcellular locations is that when KRAS is localised to the plasma 
membrane it can induce transformation, however when it is associated with the 
mitochondria it induces apoptosis.52 Activation of the RAS proteins is also thought to 
be associated with their location within the cell as they are transiently active on the 
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plasma membrane while constitutively active on the Golgi apparatus.51,53 This 
indicates that, if the localisation of the protein is altered due to the disruption of a 
localisation signal or an alteration to the proteins folding or structure due to a 
mutation, the activation and function of the protein could be significantly altered thus 
leading to disease.  
 
The localisation of the RAS proteins is regulated by the C-terminal HVR.30 It is because 
of this HVR that the RAS proteins have become typical examples of isoform and 
compartment specific signalling, as the three isoforms are differentially distributed on 
endomembranous compartments.30 This region is also thought to determine the 
function and, after multiple post-translational modifications, the localisation of the 
isoforms.30 While the post translational modifications of the HVR are responsible for 
the regulation of RAS protein localisation, the result is dynamic and can be altered by 
the activation status of RAS and its interacting proteins.30 Localisation to the Golgi 
apparatus is more pronounced for NRAS than for HRAS because NRAS is palmitoylated 
once during post translational modifications causing it to be more likely to lose 
anchorage in the plasma membrane and thus return to the Golgi apparatus than the 
dipalmitoylated HRAS.30 
 
1.2.2.3 Known mutations of the RAS family members 
The role of RAS proteins in a number of different diseases is well documented, a 
number of examples of which are outlined in Table 1.2 focusing particularly on those 
mutations that cause Noonan or Noonan-like syndromes. Table 1.2 also contains all 
known cases of Noonan syndrome caused by mutations in NRAS.  
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The most common of the disease causing mutations in the RAS proteins are those that 
impair their intrinsic GTPase activity.33 For example mutations in residue 61 of NRAS 
affect the GTP binding site and result in NRAS being constitutively activated.54 Other 
mutations such as those that affect residues 32-40, which are crucial for the putative 
effector region of RAS, result in the inhibition of biological activity and impair RAS-GAP  
binding.46 Such mutation could lead to the protein being transported or ‘stuck’ in the 
wrong location and thus not be able to carry out its proper function. This is 
particularly the case for RAS as studies have demonstrated that the localisation of the 
RAS proteins is associated with their function for example, transiently activated by 









Oliveira et al 
(2007)55 
Matsuda et al 
(2007)56 
Matsuda et al 
(2007)56 
Zenker et al 
(2007)57 
Gripp et al 
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Dessars et al 
(2009)43 
De Filippi et al 
(2009)59 
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Table 1.2: Continued 
Source 
Cirstea et al 
(2010)20 
Cirstea et al. 
(2010)20 
Runtuwene 
et al (2011)60 
Denayer 
et al (2012)61 
Denayer 
et al (2012)61 
Denayer 
et al (2012)61 
Kraoua et al 
(2012)62 
Ekvall et al  
(2015)63 


































MIM# #613224 #613224 #613224 #613224 #613224 #613224 #613224 #613224 
Type 
1x de novo, 1x 
inherited from 
mother, 1x ND 
De novo De novo ND De novo Inherited 




1x inherited,  




3 patients from 2 
unrelated families 
2 unrelated 








NRAS was the last of the three RAS isoforms to be described when it was discovered 
as a transforming gene in neuroblastoma cells in the early 1980s.64,65 Despite not 
having been studied as extensively as KRAS and HRAS due to their similarity they can 
be used as models for NRAS. The involvement of NRAS in Noonan syndrome was 
described in 2010 in a study by Cirstea et al. who found that of 917 patients, who 
were negative for previously known Noonan-associated mutations, five had a 
mutation in NRAS,20 indicating that NRAS mutations are a rare cause of Noonan 
syndrome. As of 2015, eight unrelated probands and three families, 14 individuals in 
total, have been identified to have NRAS mutations causing Noonan syndrome.63 Of 
these cases, seven are caused by a p.G60E substitution, a further three are caused by 
a p.T50I substitution and the remainder arise from one of the following substitutions; 
p.G13D, p.I24N, or p.P34L.63 
 
The study by Cirstea et al. (2010) found two different mutations in highly conserved 
regions of NRAS in four unrelated individuals.20 These c.149C>T and c.179G>A 
mutations caused p.T50I and p.G60E missense substitution in NRAS, respectively.20 
Mutations of the 60th residue had been previously described in the KRAS gene of a 
patient with CFC syndrome66 however this study was the first description of a 
mutation affecting the 50th amino acid.20 Further study found that this residue is 
exposed and located within the β2–β3 loop that connects switch I and II.20 Both 
mutations were also found to be activating mutations, causing an increase in the 
phosphorylation of MEK (MAPK/ERK Kinase) when stimulated with epidermal growth 
factors or in the presence of serum.20 
 
20 
Cirstea et al. (2010) also found that a p.T50I substitution identified in two unrelated 
boys, caused enhanced downstream phosphorylation and through molecular 
modelling showed that this residue interacts with the polar heads of the membrane 
phospholipid and thus was an integral part of NRAS membrane orientation.20 This 
mutation was hypothesised to cause an increase in the interaction of active RAS with 
its effectors causing enhanced downstream signalling consistent with a gain-of-
function mutation.20 
 
1.3 Patient background 
The patient who is the focus of this study is under the care of GSWA and was 
diagnosed with Noonan-like disease due to the phenotype displayed, including 
craniofacial anomalies such as macrocephaly, high forehead, lowset ears, 
hypertelorism, strabismus and palpebral ptosis. Musculoskeletal abnormalities 
included webbed neck, pectus excavatum and hyper-extensible joints. The patient 
also had gross motor delay. When this patient’s DNA was sequenced, no known 
Noonan associated mutations were found. However, a novel single nucleotide 
substitution (c.173C>T) in the 3rd exon of NRAS causing a missense (p.Thr58Ile) 
substitution in NRAS, was identified. A search for this mutation in the exome 
aggregation consortium (ExAC)67 database returned no result however since this 
particular mutation has not previously been identified to cause Noonan syndrome its 
role in this patient’s disease needs to be validated. 
 
This variant falls in a highly conserved region flanking the switch II motif that is 
involved in the activation and inactivation of RAS (Figure 1.5). The equivalent 
mutation has been observed in HRAS of a patient with Costello syndrome58 and KRAS 
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of a patient with Noonan syndrome-3.45 All three patients share common 
characteristics such as failure to thrive leading to short stature, cognitive impairment 




Figure 1.5: Four main regions of the RAS, modified from Cirstea et al. (2010)20 
The four main regions of NRAS are the P-Loop, Switch I (SW I), Switch II (SW II) and the 
hypervariable region (HVR), this diagram also shows a partial amino acid sequence of NRAS 
with the mutation of this study in red, note the proximity of the mutation to the switch II 
region. 
 
Similar to those mutations found by Cirstea et al. (2010) that resulted in NRAS being 
constitutively active, preliminary analysis of the novel p.T58I substitution in this study 
shows it to be a gain-of-function mutation that results in an increase in the expression 
of ERK (extracellular signal–regulated kinases) and AKT causing dysregulation of the 
RAS-MAPK pathway (M. Tartaglia and G. Baynam, personal communication, 2016). No 
further analysis of this mutation has been carried out to date.  
 
1.4 Research Aims 
This project will address the hypothesis that the c.173C>T (p.Thr58Ile) variant 
identified in the NRAS gene of a patient with Noonan-like syndrome causes a change 
in localisation and function of NRAS. These results will contribute to the validation of 




1. To determine if there is evidence to suggest that the p.T58I substitution in 
NRAS disrupts protein localisation, and/or whether the mutation affects other 
known or predicted functional domains in the protein using in silico 
bioinformatic tools. 
2. To determine the subcellular localisation of the mutant and wild type NRAS 
proteins, by visualising transiently transfected cells co-stained with specific 
organelle markers using confocal and epifluorescent microscopy. 
3. To determine the effect of the p.T58I variant on downstream cell functions, 
including cellular proliferation, cytokine production, mitochondrial function, 
and apoptosis, as time permits. 
4. Use the knowledge and techniques optimised in this study to contribute to a 
validation pipeline that can be adapted for the validation of any rare disease 
variant discovered in Western Australia. 
 
1.5 Significance of Research 
The outputs from this project will provide new knowledge that could contribute to the 
clinical management of the child with this specific rare disease. As well as providing 
proof-of-principle for the establishment of a functional pipeline that will permit the 
rapid and efficient study of protein localisation and function of other RASopathies 
identified in Western Australia with the potential for adaptability to facilitate the 
study of other rare variants.  
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2 MATERIALS AND METHODS 
Figure 2.1 provides a flow chart of the pipeline for this study, from designing of 
constructs to localisation, function and bioinformatic analyses to address the three 
main aims of this study.  Details of these methods are provided in sections below. 
 
Figure 2.1: Flowchart of the pipeline for this study. 
This includes designing of gene inserts to be synthesised and sub-cloned into 
appropriate vectors by Invitrogen GeneArt® and subsequently used to transfect cells in 
order to do localisation and functional studies. Orange boxes signify the three main 
aims of this project. 
 
2.1 Construct Design 
The coding DNA sequence for wild type NRAS (NRASWT) was obtained from the UCSC 
Genome Browser.68 To replicate the mutation found in the patient, the 173rd base of 
the wild type sequence was altered from a C (cytosine) to a T (thymine) to form the 
mutant NRAS (NRASMUT) sequence. 
 
From this four constructs were generated with Invitrogen GeneArt gene synthesis 
(Thermo Fisher Scientific); NRASWT and NRASMut both tagged with either Green 
fluorescent protein 2 (GFP2) or 3xFLAG. To design the insert to be synthesised the 
stop codon was removed from the 5’ end of the sequence, then restriction enzyme 





























of these restriction sites in both NRAS sequences, the restriction site sequences of 
HindIII was added to the 5’end and BamHI and PstI were added to the 3’ end. Two 
restriction sites were added to the 3’ end of each insert to allow sub-cloning into two 
different expression vectors:  pTagGFP2-N using HindIII and PstI and p3XFLAG-CMV-14 
using HindIII and BamHI. As codon optimisation by the GeneOptimizer® software in 
GeneArt™ modifies the input sequence to maximize translation efficacy, the option for 
codon optimisation was not selected to ensure that the sequence synthesised truly 
reflected the patient’s sequence and mutation. 
 
The synthesised gene inserts were: sub-cloned into pTagGFP2-N and p3XFLAG-CMV-
14 vectors, sequence verified, and transformed into Escherichia coli by Invitrogen™ 
GeneArt™ gene synthesis (Thermo Fisher Scientific). A diagrammatic representation of 
the construct and final translated product are shown in Figure 2.2; full plasmid maps 





Figure 2.2: Diagrammatic representation of the NRAS insert design 
a) NRAS construct with HindIII, BamHI and PstI restriction enzyme sites on the 3 and 5 prime 
ends to allow for the construct to be sub-cloned into the pTagGFP2-N and p3XFLAG-CMV-14 
vectors by Invitrogen™ GeneArt™. b) Construct as it would be when sub-cloned into the 
p3XFLAG-CMV-14 vector (NRAS-3xFLAG). c) Construct as it would be when sub-cloned into 
the pTagGFP2-N vector (NRAS-GFP2). 
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2.1.1 Protein translation   
To confirm that the addition of restriction enzyme sites and the GFP2/3xFLAG tags to 
NRASWT and NRASMut had no effect on the translation of the proteins and to ensure 
that the tags would be translated with the protein, the tagged and untagged insert 
sequences (Appendix III) were translated using the online ExPASy translate tool.70 
 
2.1.2 Solvent accessibility  
To determine if the mutation or addition of tags were likely to affect the structure of 
NRAS, the solvent accessibility of each protein sequence was assessed using the online 
tool ACCpro, which is part of SCRATCH protein predictor.71 ACCpro predicts the 
relative solvent accessibility of protein residues and annotates each as either buried or 
exposed. ACCpro was run with default parameters.  
 
2.1.3 Bacterial Growth and Plasmid extraction 
The NRASWT and NRASMut constructs were provided by GeneArt as lyophilised plasmid 
DNA and a stab culture of E. coli transformed with the plasmid. Stab cultures were 
streaked onto Lysogeny broth (LB)-agar plates containing 1% Bacto™Tryptone, 5% 
Bacto™Yeast extract and 1% sodium chloride (NaCl; Biochemicals), with 1.5% 
Bacto™Agar (Bacto™ reagents from Becton Dickinson (BD)) and supplemented with 
appropriate antibiotic: kanamycin (50µg/ml; Gibco™/Life Technologies) for GFP2 
tagged constructs and ampicillin (100µg/ml; Gibco™/Life Technologies) for 3xFLAG 
tagged constructs. Plates were incubated at 37oC for 16-18 hours before a single 
colony was selected and transferred to 1ml of LB medium with appropriate antibiotic 
and incubated for 7 hours at 37oC with constant agitation at 300rpm using a KS 4000i 
Control incubator (IKA). This starter culture was then transferred to 50ml of LB 
medium with appropriate antibiotic to be incubated for a further 16-18 hours at 37oC 
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with constant agitation at 300rpm. From these bacterial cultures both glycerol stocks 
and samples for plasmid extraction were taken. Glycerol stocks were made by adding 
850ul of bacterial culture to 150ul of 50% filter sterilised glycerol (MERCK) and were 
kept at -800C for long term storage. 
 
Plasmid DNA for the GFP2 tagged constructs was initially extracted using two different 
kits, PureYield™ plasmid miniprep system (Promega) and FavorPrep plasmid 
extraction mini Kit (FAVORGEN), to determine which kit provided the highest yield. 
After the first extraction all subsequent extractions were performed using the 
FavorPrep Kit. Both kits were used as per manufacturer’s protocol with the 
modification of a repeated elution step to ensure complete collection of plasmid DNA. 
Extracted DNA was quantified on the Nanodrop® ND-1000 spectrophotometer 
(Thermo Fisher Scientific) using FavorPrep elution buffer as the blank and with 
duplicate samples of 2µl measured. Plasmid DNA was subsequently stored at -20oC 
until required. 
 
2.1.4 Restriction enzyme digest 
Two restriction enzyme digests were performed on the GFP2 tagged constructs in 
order to confirm that the insert was of the expected size and that it was inserted 
correctly. The first was a single digest reaction using NheI-HF® (New England Biolabs) 
to linearise the plasmid. This reaction was carried out as per manufacturer’s protocol 
with an extended incubation time of 2 hours to ensure digestion was complete. A 1% 
agarose gel (Biochemicals) stained with ethidium bromide (final concentration of 
1.875µg/ml; Fisher) was loaded with 100ng of digested samples, along with their 
uncut counterparts, 1:1 with cresol red (Sigma-Aldrich). Hyperladder 1kb (2µl; Bioline) 
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was used as a molecular weight marker. Samples were electrophoresed for 120 
minutes at 130V in 1x Tris/Borate/EDTA (TBE; AMRESCO®) buffer. The gel was then 
visualised under ultraviolet light using GelDoc™ XR+ (Biorad).  
 
A second restriction digest was performed using the HindIII and PstI enzymes to cut 
the gene insert from the plasmid. A sequential restriction digest was used as different 
buffers were required for the two restriction enzymes used: Buffer E for HindIII and 
Buffer H for PstI (Promega, kindly donated by the Cancer Immunology Unit at 
Telethon Kids Institute). DNA from the pTagGFP2-N vector, NRASWT and NRASMut 
constructs was incubated for 2 hours at 370C in HindIII reaction mix made as per 
manufacturer’s instructions. Following this samples were purified using an 
UltraClean™ PCR Clean-up™ kit (MoBio) as per manufacturer’s instructions and 
quantified using Nanodrop® spectrophotometry to allow the volumes in the PstI 
reaction mix to be adjusted for the concentration of DNA. Samples were then 
incubated in PstI reaction mix made as per manufacturer’s instructions for 2 hours at 
370C. Samples were electrophoresed for 45 minutes at 120V and visualised as 
previously described. A restriction digest was not performed on 3xFLAG tagged 
constructs. 
 
2.2 Cell Culture 
Three adherent cells lines were used for the localisation studies; COS-7 (ATCC® CRL-
1651™), U87-MG (ATCC® HTB-14™) and HEK293T (ATCC® CRL-3216™; kindly donated 
by Brain Tumour Research Program at Telethon Kids Institute). All cell culture reagents 
were sourced from Gibco™/Life Technologies unless otherwise stated. COS-7 cells and 
HEK293T cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640) 
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or Dulbecco’s Modified Eagle Medium (DMEM) respectively each supplemented with 
10% foetal calf serum (FCS, Bovogen biologicals), 100UPenicillin/100µgml-1 
Streptomycin and 2mM GlutaMAX-1. U87-MG cells were cultured in Minimum 
Essential Media (MEM) supplemented with 10% FCS, 100UPenicillin/100µg ml-1 
Streptomycin, GlutaMAX-1, 1% MEM non-essential amino acids, and 1% sodium 
pyruvate. All cell lines were cultured in 25cm2 CELLSTAR® cell culture flasks (Greiner 
Bio-one), maintained horizontally in humid conditions at 37°C and 5% CO2. Cells were 
passaged regularly using TryPLE Express (Gibco™/Life Technologies) as per 
manufacturer’s recommendation to detach cells from the flask surface. 
 
Freezer stocks were made by resuspending 1x106 cells in freezing mix in cryovials for 
long-term storage in liquid nitrogen. Freezing mix was prepared as follows: 65% 
appropriate media, 25% FCS and 10% dimethyl sulphoxide (DMSO; Sigma-Aldrich). 
Prior to freezing, cell lines were tested for mycoplasma contamination using protocol 
based from Asarnow et al. (2010)72 with the following modifications. Pellet obtained 
from centrifugation of 0.5ml culture media sample was resuspended in TE buffer. 
Polymerase chain reaction (PCR) mastermix was made as follows: 1.35x PCR Buffer 
(Applied Biosystems), 4mM MgCl (Applied Biosystems), 0.67mM dNTPs (Bioline) and 
67mM Betaine (Fluka Biochemika) in water. 3µl of sample was added to 7.45µl of PCR 
mastermix, 0.5µl of the forward and reverse primers and 0.05µl of AmpliTaqGold 
(Applied Biosystem). PCR amplification was performed using an S-1000™ 
Thermocycler (Bio-Rad) set to cycling conditions previously optimised for 
AmpliTaqGold as follows: 10 minute denaturing step at 94oC, 14 cycles of 20 seconds 
at 94oC, 60 seconds of 63-56 using 0.5oC per cycle decrements and 60 seconds at 72oC. 
Then 20 cycles of 94oC for 20 seconds, 56oC for 60 seconds and 72oC for 60seconds. 
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Followed by 5 minutes at 72oC as a final extension step before samples were 
maintained at 4oC until electrophoresed on a 2% agarose gel for 40 minutes at 115V 
and visualised as previously described. 
 
2.3 Transfection 
When required for a transfection experiment, cells were counted manually using a 
Neubauer improved bright light counting chamber (Marienfeld) and an inverted 
microscope. Trypan blue (Sigma-Aldrich) exclusion was used to assess the viability of 
cells. U87-MG and COS-7/HEK293T cells were seeded into a tissue culture treated 
Greiner CELLSTAR® 24 well plate (Sigma-Aldrich) lined with a number 1, 13mm round 
coverslips (ProSciTech); or left unlined for flow cytometry related experiments, at a 
density of 7.5x105 and 5x104 cells/well respectively. Cells were then incubated in 
humid conditions at 37°C and 5% CO2 for 16-18 hours prior to transfection.  
 
Initially cells were transfected using Lipofectamine® LTX with Plus™ Reagent 
(Invitrogen™/Life Technologies), however after the completion of this product a 
similar, more efficient product Lipofectamine® 3000 (Invitrogen™/Life Technologies) 
was used. This alteration was unlikely to have any effect on the results obtained as 
both products use the same principle. In both cases reagent concentrations were as 
the manufacturer’s protocol. Briefly plasmid DNA (0.5 μg/well) was incubated in 
humid conditions at 37oC and 5% CO2 with Plus™ /3000 reagent in OPTI-MEM 
(Gibco™/Life Technologies) for 15 minutes. The mixture of plasmid DNA and Plus/3000 
was then added drop-wise into a mix of diluted Lipofectamine™ in OPTI-MEM so as to 
promote the formation of miscelles and incubated for a further 30 minutes. During 
the incubation of the Lipofectamine®-DNA mixture, cells were washed twice with 
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serum free media (appropriate media + 2mM GlutaMAX-1) then incubated at 37°C 
and 5% CO2 for 15 minutes in serum free media. Following which 50µl of the 
Lipofectamine® mixture was added directly to the serum free media into each well to 
be transfected and incubated for 3 hours at 37°C and 5% CO2. The 
Lipofectamine®/media mixture was then removed from wells and replaced with 
complete media without antibiotics (appropriate media, 10%FCS, 2mM GlutaMAX-1) 
and incubated at 37°C and 5% CO2 for 27 hours. 
 
2.3.1 Transfection efficiency 
Multiple transfection efficiency experiments were performed to ensure that: the two 
Lipofectamine® reagents gave efficient levels of transfection, all three cell types had 
sufficient levels of transfection and to determine the most efficient length of time for 
which the cells should be transfected. Three time points were used; 24, 30 and 48 
hours, after the addition of Lipofectamine® reagent to the wells.  
 
To determine transfection efficiency cells were transfected as previously described in 
a 24 well plate without coverslip lining. After the appropriate incubation time, cells 
were detached using TryPLE Express, harvested into individual round bottom tubes 
(BD falcon™) and fixed with 2-4% paraformaldehyde (Sigma-Aldrich) for 15 minutes. 
After incubation cells were washed twice with FACSWash containing 10% Bovine 
serum albumin (Sigma-Aldrich) and 10% EDTA (Sigma®) in PBS with cells being 
pelleted by centrifugation for 5 minutes at 201g between each step. Cells were then 
resuspended in FACSWash and stored at 4oC until analysed using the LSRII flow 
cytometer (BD). Samples were analysed in duplicate collecting a minimum of 10,000 
events per run. GFP2 fluorescence was measured using the 488nm laser. Cells that 
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had been through the transfection process with no DNA (no DNA control) were used 
to determine the gating of GFP2 negative (non-transfected) and positive (transfected) 
cell populations as shown in Figure 2.3. The 30 hour time point was used in all 






Figure 2.3: Gating strategy for transfection efficiency experiments. 
The cells of interest were selected as seen in a. this formed population 1(P1), from this a 
polygonal gate was drawn excluding all events in the no DNA control as shown in b. this 
forms population 2(P2). P2 correlates to those cells that are GFP2 positive as seen in c. 
 
2.4 Localisation studies 
2.4.1 Bioinformatic analysis  
There were two main aims for the bioinformatic analysis section of this study. Firstly 
to determine the predicted localisation of NRASWT and if the mutation harboured by 
the patient was predicted to alter this localisation. This allowed for the organelle 
markers used in the localisation studies to be selected. Secondly to identify if there 
was any bioinformatic evidence to suggest that the addition of the GFP2 or 3xFLAG 
tags, especially the large GFP2 tag, might influence the localisation of NRASWT and/or 
NRASMUT constructs. To address these aims the online localisation tools described 
below were used. Full sequences for the tagged and untagged NRASWT and NRASMUT 
proteins analysed with these tools are provided in Appendix IV. All tools were used on 
default settings. 
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2.4.1.1 cNLS Mapper  
cNLS mapper73 is an online tool which identifies importin α-dependent nuclear 
localization signals. This tool annotates the input sequence with the localisation signal 
and its score, this score relates to the level of activity of the NLS. Higher scores 
indicate stronger NLS activities. A score of greater than 8 indicates exclusive 
localisation to the nucleus, 7 or 8 indicates partial localisation to the nucleus, between 
7 and 3 indicates localisation to both the nucleus and the cytoplasm, and a score 
below 3 indicates cytoplasmic localisation.73 By default this tool restricts its analysing 
to the terminal 60 amino acid regions, the option to search the entire sequence was 
chosen to ensure no signals were overlooked. This tool was developed based on 




Hum-mPLoc 2.074 is an adapted version of Hum-PLoc which can determine the 
predicted localisation of human proteins which may have more than one location in a 
cell at one time or that move between multiple locations. This tool predicts if the 
protein of interest localises to any of 14 different subcellular locations including 
cytoplasm, cytoskeleton, endoplasmic reticulum, endosome, Golgi apparatus, 
lysosome, and plasma membrane. These predictions are based on a dataset that 





LocSigDB76 is a database of 533 experimentally-validated localisation signals for eight 
different subcellular locations that have been manually curated from the literature. 
This tool annotates the input sequence with the localisation signal, the source of this 
signal, PubMed references and the protein in which the signal was identified.77  
 
2.4.1.4 WoLF PSORT 
WoLF-PSORT78 predicts the subcellular localisation of proteins from their amino acid 
sequence based on amino acid sequence information and a set of rules derived from 
experimental observations. The animal specific database was used for this prediction. 
This database used was curated from UniProt79 and Gene Ontology80 and contains 
known sorting signals, amino acid composition and functional motifs for 12,771 
animal proteins.78  
 
2.4.1.5 BaCelLo 
BaCelLo81 is a prediction tool for the subcellular localization of eukaryotic proteins. 
This can classify proteins as localising to one of four locations: secretory pathway, 
cytoplasm, nucleus or mitochondrion based on the whole protein sequence and its N- 
and C-terminal regions.81 The animal option was selected when running this tool, 




For localisation studies the media was removed from the wells 30 hours post 
transfection (Section 2.3) and cells were fixed with 2-4% paraformaldehyde for 15 
minutes. The cells were washed thrice with 1x Phosphate Buffered Saline (PBS; 
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Biochemicals) and subsequently incubated in permeabilisation/blocking solution (PBT) 
containing 1% BSA and 0.25% Triton-X 100 (ICN Biomedicals) in PBS for 30 minutes at 
room temperature. Cells were then incubated overnight at 4oC with primary 
antibodies diluted in PBT to their optimal concentration as described below (Section 
2.4.2.1). 
 
2.4.2.1 Antibody optimisation 
Optimal primary antibody concentration/dilution was determined through an 
antibody titration experiment in which COS-7 cells were seeded, grown, fixed and 
permeabilised/blocked. These cells were then incubated with varying 
concentrations/dilutions of primary antibody in PBT as determined by the 
manufacturer’s recommendations. Information on the primary antibodies used in this 
study is summarised in Table 2.1. Cells were then incubated with the appropriate 
secondary antibody (Section 2.4.3), counterstained with Counterstained with 
NucBlue® fixed cell stain, as described in section 2.4.3, and visualised using the C2+ 
confocal microscope system (Nikon; Section 2.4.6). From this the lowest concentration 
or dilution, as indicated, that gave a clear picture with staining specific to the 
respective sub-cellular location and low levels of background was selected for ongoing 
experiments. Controls included; no primary antibody, no secondary antibody and no 
antibodies, as well as cells transfected with the ptagGFP2-N vector alone and those 
transfected with no-DNA added. 
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Table 2.1: Information on the source, host, clonality and localisation for each primary antibody used in this study and the 
concentrations/dilutions used in the antibody optimisation experiment. 
Antibody Reference 
Number 
Company Clonality Marker 
Localisation 
Host Concentration/Dilutions tested Optimal 
Concentration/Dilution 1 2 3 






Rabbit 2 µg/ml 1 µg/ml 0.5 µg/ml 0.5µg/ml 
















Rabbit 1:100 1:150 1:250* 1:500* 
Anti-Calcium Pump pan 
PMCA ATPase antibody 
[5F10]ϯ 
ab2825 abcam Monoclonal 
Plasma 
membrane 
Mouse 1:200 1:500 1:1000 1:200 
Anti-LAMP1 antibody ab24170 abcam Polyclonal Lysosomes Rabbit 
Optimised by Emily Kempin, 
Genetics and health 
 
0.5µg/ml 








ϯ Antibody unpurified thus unable to be quantified, therefore dilutions shown are based off of specific product. *later altered to 1:500 after this 
dilution was found to produced images of a higher quality 
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2.4.3 Secondary antibodies  
Following overnight incubation at 4oC with primary antibodies, coverslips were 
incubated at room temperature in the dark for 1 hour with 1 drop (~25µl) of Alexa 
Fluor® 594 conjugated goat anti-rabbit IgG (R37117; Molecular Probes®/Life 
technologies™) or Alexa Fluor® 594 conjugated goat anti-mouse IgG (R37121; 
Molecular Probes®/Life technologies™) secondary antibodies in 1ml of PBT. Cells were 
then counter stained for 5 minutes with 1 drop (~25µl) of NucBlue® fixed cell stain 
ReadyProbes™ reagent (R37606; Molecular Probes®/Life technologies™) in 1ml of 
PBT. Between all staining steps cells were washed with 1x PBS thrice for 5 minutes 
each to reduce non-specific binding.  
 
2.4.4 Mitotracker 
A selected number of coverslips with transfected U87-MG cells were stained with 
MitoTracker® Orange CMTMRos (M7510; Molecular Probes®/Life technologies™). This 
staining protocol was very different from those using the other antibodies as 
MitoTracker has its own conjugate. Media was removed from the wells 30 hours post 
transfection (Section 2.3) and cells were then incubated in MitoTracker diluted to 
500nM in Hank's Balanced Salt Solution (Sigma-Aldrich) warmed to 37oC for 45 
minutes in humid environment at 37oC and 5% CO2. Following incubation cells were 
counterstained with 1 drop (~25µl) of NucBlue® Live ReadyProbes® Reagent (R37605; 
Molecular Probes®/Life technologies™) in 1ml of PBT for 5 minutes. Cells were washed 
thrice with sterile PBS warmed to 37oC, then fixed in 2-4% paraformaldehyde for 15 
minutes and washed again with PBS prior to mounting. 
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2.4.5 Mounting of coverslips 
After the final wash coverslips were mounted onto SUPERFROST®PLUS microscope 
slides (LabServ). Two different mountants were used; VECTASHIELD® Hard set™ 
mounting medium (Vector Laboratories) for COS-7 and HEK293T cell experiments and 
Immu-Mount™ (Thermo Scientific™ Shandon™) for all U87-MG cell experiments. Both 
mountants were used as per manufacturer’s recommendations. VECTASHIELD® and 
Immu-Mount™ have a refractive index of 1.46 and 1.586 respectively. When using 
Immu-Mount™ slides were left to dry for 2-4 hrs and then coverslip edges sealed with 
clear nail varnish (Cutex). All slides were stored in the dark at 4oC until and after 
visualisation using the C2+ confocal microscope system (Nikon).  
 
2.4.6 Epifluorescent and Confocal imaging  
Cells were initially imaged using epifluorescence, a technique which utilises a broad 
light source passing through specific filter cubes. This technique was used for antibody 
optimisation. The cubes used were mCherry B NTE (641nm; Semrock) for the Alexa 
fluor® 594 stained organelles, UV-2A (440nm; Nikon) for the DAPI stained nucleus and 
GFP-3035D-NTE(510nm; Semrock) for the GFP2 and 3xFLAG constructs. Epifluorescent 
images were taken with the Nikon DS-U3 driver of the NIS-Elements-C software 
provided with the C2+ confocal microscope. Images were taken using a Plan Apo 20x 
DIC M NA0.75 objective (Nikon).  
 
Localisation study images were taken using confocal microscopy. The following lasers 
were used:  561nm, 488nm and 405nm lasers for Alexa Fluor® 594, FITC/GFP2 and 
DAPI respectively. Z-Series images were taken sequentially with the Nikon confocal 
driver of the NIS-Elements-C software. Images were taken using Plan Apo VC 60x 
NA1.4 oil immersion objective (Nikon) with a step of 0.5µm between images and 
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pinhole setting of 1.2AU. Laser power, gain and offset were adjusted using control 
slides to eliminate background fluorescence and were kept constant within an 
experiment. The top and bottom sections of a z-series were chosen arbitrarily based 
on what a particular cell or group of cells dictated. Individual images from a stack 
were chosen based on quality.  
 
All Images were saved in the program’s default format of ND2 as well as single images 
saved as TIFF (converted to 8bit RBG) or JPEG. Images were altered post acquisition 
using look up tables which were set to show no background staining using control 
slides and kept constant for all other slides pertaining to the control. Scale bars were 
added using ImageJ.82 
 
2.5 Western blot 
2.5.1 Sample preparation 
Protein was extracted from HEK293Tand U87-MG cells that were transfected as 
previously described. The extraction process involved washing the cell monolayer in 
sterile PBS twice before lysing cells with radioimmunoprecipitation assay (RIPA) 
buffer, containing 50mM Tris (AMRESCO), 150mM NaCl, 0.5% sodium deoxycholate 
(Sigma-Aldrich), 0.1% sodium docecyl sulphate (Sigma) and 1% IGEPAL (Sigma), and 
then incubating at 4oC for 10 minutes before using a 25cm cell scraper (Sarstedt) to 
collect the cell lysate and debris. This was incubated on ice for 10minutes then 
centrifuged at 15,700g for 20 minutes at 4oC (Eppendorf 5415 R) to collect the 
supernatant. Protein concentration was determined by a direct-detect assay-free card 
and direct detect machine (Millipore) on default settings prior to being stored at -80oC 
until required. 
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In preparation for western blotting 5.3µl of NuPAGE® 4x LDS sample buffer 
(Novex®/Life technologies™) and 1.75µl NuPAGE® 10x sample reducing agent 
(Novex®/Life technologies™) were added to 50µg of protein samples and the volume 
made up to 20µl using RPIA buffer. Samples were heated at 70oC for 10 minutes in 
Thermomixer Comfort (Eppendorf) heating block and quenched on ice for at 2 
minutes before loading onto gel. 
 
2.5.2 Sample Loading 
NuPAGE 4 –12% Bis-Tris gels (Invitrogen®/Thermo Fisher Scientific) were washed 
thoroughly with distilled water before being loaded into a gel tank. Running buffers: 
200ml of inner chamber running buffer (5% NuPAGE® 20x MES SDS running 
buffer(Novex®/Life technologies™) and 0.15% NuPAGE® antioxidant (Novex®/Life 
technologies™) in MilliQ water) and 500ml of outer chamber running buffer (5% MES 
buffer in MilliQ water), were added ensuring no mixing.  Wells were rinsed gently with 
inner chamber running buffer and 20µl samples loaded into each well. 7µl of Precision 
Plus Protein™ Kaleidoscope™ (Bio-Rad) was used as a size standard. The gel was run 
for 70 minutes at 140V in an XCell SureLock™ Mini-Cell Electrophoresis System 
(Thermo Fisher Scientific). The gel was then placed between the bottom and top 
sections of a Trans-Blot® Turbo™ mini nitrocellulose transfer pack (Bio-Rad). Protein 
was transferred to the PVDF membrane using Trans-Blot® Turbo™ transfer system 





2.5.3 Blocking and staining of membrane 
Post transfer, the membrane was incubated for 2 hours on platform mixer (Ratek) at 
80rpm  in blocking solution (5% skim milk powder in 1x TBST (1x Tris-buffered saline, 
0.1% Tween 20); Sigma-Aldrich), then washed thrice for 5 minutes each with 1x TBST 
at 80rpm. The membrane was cut in half with one half incubated on rotator overnight 
at 4°C in anti-GFP antibody (G10362;Life technologies™) diluted 1:1000 in antibody 
diluent (1% skim milk powder in TBST) and the remaining half incubated in diluent 
alone as the  no primary antibody control. Both membrane halves were washed thrice 
for 5 minutes each with 1x TBST before being incubated on rotator at room 
temperature for 2 hours in Amersham ECL anti-rabbit IgG, horseradish peroxidase-
linked whole Ab (0.19µg/ml; NA934; GE Healthcare). Protein was detected using the 
Amersham ECL plus chemiluminescence system (GE Healthcare) and visualised using 
GelDoc™ MG (Bio-Rad) with an exposure time of 180 seconds. 
 
2.6 Functional analysis 
2.6.1 Apoptosis assay  
To determine the effects of the mutation in NRAS on apoptosis, U87-MG cells 
transfected with either NRASMUT or NRASWT were compared in assays using Andy 
Fluor™ 594 conjugated Annexin V (Applied BioProbes). This product binds to 
phosphatidylserine labelling apoptotic cells which can then be detected using flow 
cytometry.  
 
This product was used as per manufacturer’s protocol, with the addition of LIVE/DEAD 
fixable Near-IR dead cell stain (Molecular Probes®/Life Technologies™) to distinguish 
dead cells from apoptosing cells. Briefly: 1x106 U87-MG cells were transfected as 
previously described (Section 2.3). An apoptosis positive control was prepared by 
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incubating one well of untransfected cells in 5mM sodium azide for 5 minutes after 
which cells were washed and incubated in appropriate media for a further 24 hours. 
Post transfection period cells were harvested using TryPLE express, washed with cold 
PBS and stained with 5 ng/µl LIVE/DEAD stain in the dark at room temperature for 30 
minutes. Cells were then centrifuged for 5 minutes at 201g (Eppendorf 5810R) and 
resuspended in annexin-binding buffer containing 10 mM HEPES (ICN Biomedicals), 
140 mM NaCl and 2.5 mM CaCl2.2H2O (ICN Biomedicals). To this 0.625 μg/ml Andy 
Fluor™ 594 Annexin V was added and samples were incubated in the dark at room 
temperature for a further 15 minutes before being placed on ice until analysis using 
flow cytometry.  
 
Samples were analysed using the LSRFortessa (BD), collecting a minimum of 50,000 
events per run. An initial gate was set using a no-DNA control, these were unstained 
cells that had been through the transfection process but with no DNA added. The 
population of GFP2 positive (transfected cells) could then be identified, and within this 
population the proportions of live, dead or apoptosing cells determined. The following 
lasers were used: 488nm, 561nm and 640nm for GFP2, Andy Fluor™ 594 Annexin V 
and Live/Dead stain respectively. Further controls for this experiment included, cells 
stained with each stain individually, a sample of apoptosis positive cells and cells fixed 
with 2% paraformaldehyde for 15 minutes as a control for the LIVE/DEAD stain.  
 
2.6.2 Functional motifs  
A bioinformatic analysis of the insert sequences was performed to determine if there 
was the potential for any other functions to be disrupted by the mutation. The tagged 
and untagged insert sequences were analysed using MOTIF search 
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(http://www.genome.jp/tools/motif/), which annotates the amino acid sequence of 
interest with putative functional motifs and binding domains present based on a 
database of known motifs. This tool was used on the default Pfam83 database. The 
same sequences were also analysed using the CD-Search tool84 which searches the 





Previous studies have observed NRAS interacting with multiple subcellular locations 
including the Golgi apparatus,50,51,85 plasma membrane,30 endoplasmic reticulum50,51 
and the inner and outer membranes of the mitochondria.34,86 There are also studies 
which suggest that the activation of the RAS isoforms is associated with their 
localisation and in turn their function. For example the RAS proteins are known to be 
transiently active on the plasma membrane while constitutively active on the Golgi 
apparatus.51 Therefore it was hypothesised that if the localisation of NRAS was altered 
due to the disruption of a localisation signal or it’s normal folding/structure, the 
activation and function of the protein could be significantly affected leading to 
disease. 
 
 In turn the function of the RAS proteins has been closely linked to their localisation. 
For example it is known that HRAS is only able to activate the RAF1–ERK pathway 
while it maintains an association with the endoplasmic reticulum.51 Similar 
location-specific functions have been observed from the KRAS isoform as well; KRAS 
associated with the plasma membrane can induce transformation whereas 
mitochondria associated KRAS leads to apoptosis.52 Due to its dependence on 
localisation and activation, the function of NRAS, which has a major role in many 
pathways, is likely to be severely disrupted in the instance of altered localisation and 
or activation. 
 
Preliminary analysis of the novel p.T58I substitution by another group showed it to be 
a gain-of-function mutation meaning that NRAS was active more so than naturally (M. 
Tartaglia and G. Baynam, personal communication, 2016). This preliminary data also 
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identified that this gain-in-function results in increased expression of ERK and AKT. 
AKT has a major role in regulating cell survival87 and an increase in active AKT has 
been shown to protect a number of cell lines, including COS-788 and MDCK89 epithelial 
cells, from apoptosis induced in a number of ways. Therefore, it was hypothesised 
that an increase in AKT caused by the mutation would result in lower levels of 
apoptosis. Since apoptosis is a programmed form of cell death that plays an important 
role in tissue homeostasis an imbalance in this process is likely to have serious 
consequences. 
 
The importance and connection of activation, localisation and function means that 
knowing the effects of the mutation on NRAS localisation and function is vital. A 
combination of online bioinformatic tools and a literature search were used to predict 
the effect of the mutation on the protein’s localisation. This was then complemented 
by in vitro localisation studies in which cells were transfected with NRASWT or NRASMUT 
constructs tagged with GFP2 or 3xFLAG tags (Section 2.3) and stained with organelle 
markers (Section 2.4.2)  to determine experimentally where the proteins were 
localising. To identify the mutation’s effect on apoptosis an assay to detect and 
quantify apoptosis was performed. Other potential effects of the mutation on 
function were predicted using bioinformatics tools to identify the presence of 





This chapter relates to the results for four main aims:  
1. To determine if there is evidence to suggest that the p.T58I substitution 
identified in NRAS disrupts its localisation using in silico bioinformatic tools and 
literature. 
2. To determine the subcellular localisation of NRASWT and NRASMUT, by 
visualising transiently transfected cells, co-stained with specific organelle 
markers using confocal and epifluorescent microscopy. 
3. To determine if the p.T58I substitution leads to a decrease in apoptosis 
through the use of an apoptosis assay 
4. To determine if there is any evidence to suggest that any other functions of 
NRAS would be disrupted by the mutation through the use of bioinformatic 
tools 
 
3.2 Bioinformatic analysis  
3.2.1 Translation and solvent accessibility 
The translation of the NRASWT and NRASMUT inserts was examined using the online 
ExPASy translate tool.70 This tool predicted that the mutation would have no effect on 
the translation of the full protein and that the only difference between the wild type 
and mutant proteins was the 58th amino acid which was predicted to be an isoleucine 
in NRASMUT and a threonine in NRASWT. The tool also predicted that the tagged inserts; 
NRAS-GFP2 and NRAS-3xFLAG, would be translated into a single uninterrupted 
protein. The predicted amino acid sequences for the tagged and untagged inserts are 
provided in Appendix IV. 
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The predicted structure of these translated sequences was explored using AccPro71 
which annotates each residue as either exposed (e) or buried (-) based on the amount 
of surface area of the residue that is accessible to a solvent. In all of the sequences 
that were studied: NRASWT and NRASMUT tagged and untagged, the only residue that 
was predicted to change was the last amino acid prior to remainder of the restriction 
enzyme site used to sub-clone the insert into expression vectors, this residue was 
predicted to be buried in the constructs rather than exposed, highlighted in Figure 3.1. 
The addition of the 3xFLAG and GFP2 tags was not predicted to alter the structure of 
NRAS. The mutation site, shown in red, was predicted to be buried in both the wild 






Figure 3.1: Solvent accessibility of tagged protein sequence as predicted by AccPro. 
a) and b) show residues predicted to be exposed (e) and buried () for the NRAS and GFP2 
tagged protein sequences respectively. The mutation site is shown in red and the only 
residue predicted to have different accessibility is highlighted in blue. The protein sequence 
for the remainder of the restriction enzyme site, multiple cloning region and the GFP2 tag is 
highlighted in green. The same result was seen for all constructs (data not shown).  
 
3.2.2 Prediction of subcellular localisation of NRASWT and NRASMUT 
To determine if the p.T58I substitution in NRAS caused disruption of any localisation 
signals or caused the protein to localise differently the tagged and untagged protein 
sequences as predicted by the ExPASy translate tool (Section 3.2.1) were examined for 
localisation signals curated from literature as well as using online bioinformatic tools. 
These tools provided a predicted localisation based on their databases as well as 
manually from signals curated from literature. 
 
 

































3.2.2.1 Nuclear localisation 
A review of literature revealed that a number of different signals are known to be 
associated with nuclear localisation, these fall under the classical or non-classical 
categories.90-92 Such signals include monopartite signals like PKKKRKV91 and  bipartite 
signals which consist of two groups of basic amino acids separated by a group of 
approximately 10 amino acids, for example KR[PAATKKAGQA]KKKK which is one of the 
most well characterised bipartite signals.90,92 No such sequences were detected within 
the wild type or mutant sequences nor in the tagged protein sequences.  
 
In addition to manual analysis of the protein using signals curated from literature, the 
insert sequences were analysed with the online tool cNLS Mapper73,93 which highlights 
importin α-dependant nuclear localisation signals. This analysis showed no predicted 
signals when using a mid-range cut-off of a score greater than 5, which predicts 
nuclear specific localisation signals. When the threshold was decreased to a score of 3, 
which indicates nuclear/cytoplasmic localisation, a number of signals were found 
Figure 3.2. This tool predicts that there are weak nuclear and cytoplasmic localisation 
signals within both of the GFP2 (Figure 3.2.b) and 3xFLAG (Figure 3.2.c) tagged NRAS 
inserts therefore potentially directing NRAS to these locations. While there were also 
NLS sequences identified in the untagged inserts (Figure 3.2.a), each tag resulted an 
additional localisation signal. The mutation site, however, is not within any of these 
localisation signals and was not found to introduce a previously unseen NLS or abolish 





Figure 3.2: Nuclear localisation signals as predicted by cNLS Mapper. 
The a) NRAS, b) GFP2 tagged NRAS and c) 3xFLAG tagged NRAS, protein sequences were 
analysed using cNLS Mapper using a cut-off score of 3.0. This score indicates the strength of 
the NLS sequence with 3, 4 and 5 indicating nuclear and cytoplasmic and 7-10 indicating 
varying levels of nuclear localisation. The mutation site is underlined and the GFP2 and 
3xFLAG tag sequences are highlighted in green. 
 
  






























3.2.2.2 Other subcellular compartments 
While NRAS has been shown in multiple studies to localise to a number of organelles, 
the effect of the mutation and addition of tags were not previously known, therefore 
all sequences were analysed using a number of tools. The results of these analyses led 
to the general consensus that both the wild type and mutant, tagged and untagged 
proteins would likely localise to the cytoplasm, plasma membrane and/or nucleus. A 
full summary of the prediction from these tools is shown in Table 3.1. Specifically, the 
online tools HumPLoc, PSORT II, WoLF PSORT and BaCeLo predict that the proteins are 
most likely to be cytoplasmic (Table 3.1). HumPLoc and PSORT II also predict a plasma 
membrane localisation of all sequences analysed (Table 3.1). These tools indicate that 
there is no difference in localisation between the wild type and mutant forms of 
NRAS, however WoLF PSORT and PSORTII predict that the addition of the tags could 
result in altered localisation. WoLF PSORT predicted that the GFP2 tagged constructs 
potentially localise to the mitochondria, therefore this needs to be carefully 
interpreted in the localisation studies.  
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Table 3.1: Predicted localisation of the tagged and untagged NRASWT and NRASMUT proteins determine using a number of online bioinformatics 
tools.  
Tool NRASWT NRASMUT NRASWT-GFP2 NRASMUT-GFP2 NRASWT-3xFLAG NRASMUT-3xFLAG 
Hum-mPLoc 
- Plasma membrane 
- Cytoplasm 
- Plasma membrane 
- Cytoplasm 
- Plasma membrane 
- Cytoplasm 
- Plasma membrane 
- Cytoplasm 
- Plasma membrane 
- Cytoplasm 










































- Vesicles of secretory 
system 
- Plasma membrane 
- Golgi apparatus 
- Cytoplasm 
- Vesicles of secretory 
system 
- Golgi apparatus 















- Vesicles of secretory 
system 








BaCelLo - Cytoplasm - Cytoplasm - Cytoplasm - Cytoplasm - Cytoplasm - Cytoplasm 
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LocSigDB, which provides an annotated report of predicted signals for localisation 
rather than a location itself, predicted that the proteins would localise to the 
lysosomes or endoplasmic reticulum. This tool highlighted a number of sequences 
which are known to be associated with localisation to the lysosome and endoplasmic 
reticulum as shown in Figure 3.3. These signals do not differ between NRASWT and 
NRASMUT, however, there were additional localisation signals identified in the GFP2 
tagged constructs. These are shown in red and blue below and indicate that the GFP2 
tag may dictate the localisation of NRAS to the melanosome, lysosome and/or 








Signal Coordinate(s) Localization 
[DE]x{3}L[LI] 395-401, 421-427 Lysosome|melanosome 
Yx{2}[VILFWCM]  3-7, 63-67, 156-160, 244-248 Lysosome 
Dx{1}E 46-49 Endoplasmic reticulum 
[HK]x{1}K 282-285, 310-313, 331-334 Endoplasmic reticulum 
 
Figure 3.3: Localisation signals identified in the NRAS-GFP2 using LocSigDB.  
The protein sequence of the GFP2 tagged NRAS proteins were analysed, there was no 
difference between the wild type and mutant. The mutation site is in bold and 
underlined, no localisation signal was found to overlap with this residue. The residues 
highlighted refer to the localisation signals shown in the same colour below. The signals 
in red and blue are unique to the GFP2 tagged constructs while the other signals were 
found in the NRAS and NRAS-3xFLAG sequences (data not shown). The GFP2 tag is 




3.2.2.3 Post-translational modifications 
A review of the literature found that all three RAS isoforms undergo post-translational 
modifications to their hyervariable region (HVR), a process which is involved in their 
ability to stably interact with membranes.30 The first step is the farnesylation of the 
cysteine of the C terminal CAXX motif,30 highlighted in green in Figure 3.4 This is 
followed by further methylation which allows the RAS proteins to interact with the 
endoplasmic reticulum.30 This binding is then supported by a second motif. For NRAS 
and HRAS the second motif consists of one or two amino acids respectively shown in 
red in Figure 3.4 which are palmitoylated allowing plasma membrane localisation.30 
NRAS then has a third motif of basic/hydrophobic amino acids shown in yellow in 




Figure 3.4: Diagram of the HVR of RAS modified from Henis et al (2010)30 
This hypervariable region contains three motifs which are modified post translation to allow 
that proteins to localisation to the necessary sub-cellular locations. 
 
3.3 Quality Control  
Prior to localisation studies, the constructs were studied to ensure that the insert was 
present and that the NRAS-GFP2 protein was expressed. This was done to ensure that 
the constructs were designed and synthesised as expected and to validate the quality 




3.3.1 Restriction digest  
To confirm that the gene insert was sub-cloned into the vectors and that the sequence 
was approximately the correct length two restriction digest experiments were 
performed. The first was a single digest using NheI to linearise the constructs and 
allow the larger size of the NRAS constructs compared to the vector alone to be 
observed. This confirms the presence of the insert within each construct and its 
absence from the vector alone (Figure 3.5). The uncut controls in lanes 3, 5 and 7 of 
Figure 3.5 confirm that the cut samples were appropriately cleaved as the uncut 




Figure 3.5: Restriction digestion of GFP2 tagged constructs and pTagGFP2-N vector 
These plasmids were linearised with NheI and electrophoresed alongside their uncut 
counterparts. Note that the larger size of the NRAS constructs than the vector alone which 
confirms the presence of the insert. 
 
A second restriction digest was then performed on the GFP2 tagged constructs to 
determine the size of the insert itself and to confirm that it was indeed sub-cloned 
into the expression vector. This restriction digest involved the sequential cutting of 
the plasmid DNA with first HindIII then PstI (Section 2.1.4) so as to result in two 
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fragments of DNA: the NRAS construct which is 579bp, and the remainder of the 
plasmid which is 4717bp. This digest showed that there were two fragments of the 
expected length in both the NRASWT and NRASMUT samples. The excised insert in each 
of these samples is indicated by an arrow in Figure 3.6, these bands are weak due to a 
deficit of sample loaded into the gel. The band correlating to the insert was not 
present in the pTagGFP2-N sample as expected (Figure 3.6). An uncut pTagGFP2-N 
vector sample was used as a control for the restriction enzymes to ensure that they 
worked, this sample showed the expected supercoiled DNA band seen at 
approximately 4000bp however there was also an additional band at approximately 
600bp which was not expected. Since this band was not seen in the cut vector control 
it is possible that it is the result of contamination with and partial digest of the vector 
by the restriction enzymes. It is possible this is a result of non-standard conditions 
which can cause restriction enzymes to cleave at non-conocal sites, a phenomenon 






Figure 3.6: Sequential restriction digest on GFP2 tagged constructs. 
These plasmids were digested using HindIII and PstI to excise the insert from the vector. The 
arrows indicate bands at approximately 579bp which correlate to the bands expected of the 
excised NRAS insert.  
 
3.3.2 Western Blot  
To further confirm that NRASWT and NRASMUT were not only within the plasmid but 
also that the NRAS-GFP2 protein was being expressed, a western blot was performed.  
This utilised protein extracted from U87-MG cells transfected with GFP2 tagged 
constructs, the pTagGFP2-N vector or left untransfected for the negative control. Both 
the NRASWT-GFP2 and NRASMUT-GFP2 proteins are expressed, as shown by the bands 
in lanes 3 and 4 respectively, which are ~49.83 kilodaltons (kDa) matching the 
predicted size of the NRAS and GFP2 proteins (Figure 3.7.a). The pTagGFP2-N vector 
produced a band which is approximately 28.6kDa in size, this correlates to the size of 
the GFP2 protein. The primary only control showed no bands as expected (Figure 





Figure 3.7: Image of Western blot membranes taken at 180seconds of exposure. 
Bands of approximately ~49.83 kDa were observed in the the NRASWT-GFP2 and NRASMUT-
GFP2 samples (red arrows) and 28.6kDa in the vector only sample(blue arrow). a) 
membrane stained with both the anti-GFP primary antibody and the appropriate secondary 
antibody. b) No primary control which was incubated in the secondary only. Lane details are 
as follows: 1. pTagGFP2-N vector, 2. No DNA(negative control), 3. NRASWT and 4. NRASMUT, 
with kaleidoscope ladder (Bio-Rad) used as a protein size standard. 
 
3.4 Optimisation of Methods 
Optimisation of the protocols to be used for transfection studies was undertaken.  
This included optimising the transfection incubation period, the cell line used, 
antibody concentrations and antibodies used. 
 
3.4.1 Transfection efficiency 
The efficiency of transfection using two Lipofectamine® reagents in HEK293T and U87-
MG cells was determined at 24, 30 and 48 hours. Cells were transfected and then 
analysed using flow cytometry (Section 2.3.1). The time points originally chosen were 
24 and 48 hours as a standard length of time for transfection. The results of this 
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experiment, which was carried out in HEK293T cells with Lipofectamine® LTX with plus 
reagent, found that there was no noteworthy difference between the two time points 
with approximately 38% transfection at 24 hours and 32% at 48 hours. This lead to the 
decision that either time point was acceptable (Table 3.2). A third time point of 30 
hours was subsequently trialled; this was chosen to match work that had previously 
been done on the same NRAS mutation. The 30 hour transfection optimisation was 
similarly performed in HEK293T cells with Lipofectamine® LTX and plus with 
transfection rates similar to those at 24 and 48 hours observed (Table 3.2). Since there 
was very little difference between the three times points it was determined that a 30 
hour incubation would be used for all experiments to provide conditions comparable 
to those used by collaborators also working on this mutation (M. Tartaglia and G. 
Baynam, personal communication, 2016).  
 
An additional efficiency experiment was performed when a new Lipofectamine® 
reagent (3000) and cell line (U87-MG) were being used. This experiment used the 
same 30 hour incubation period in U87-MG cells transfected using Lipofectamine® 
3000. The results of this are similar to those of the previous efficiency experiments 
(Table 3.2).  
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Table 3.2: Transfection efficiency results. 
 HEK293T and U87-MG cells were transfected with either Lipofectamine® LTX with plus 




3.4.2 Antibody optimisation  
Optimisation of the dilution/concentration of primary antibody to be used is essential 
in order to get good quality images. The dilutions tested (Section 2.4.2.1) were based 
on the recommended dilution provided by the manufacturer. The aim of this was to 
determine the lowest concentration that would provide clear images with little 
background and specific staining of the organelle of interest. The results of this 
optimisation for each antibody are shown in Figure 3.8. The dilution of GOLGA2 was 
later changed to 1:500 as the images produced using a dilution of 1:250 were too 
bright causing images to look overexposed. All images shown in this study used 
primary antibodies as follows; 0.5ug/ml for Glut1 and dilutions of 1:500, 1:100 and 
1:200 for GOLGA2, TGN38 and Anti-calcium pump pan PMCA ATPase (PMCA) 
respectively. As seen in Figure 3.8 the TGN38 antibody gave very low levels of 
fluorescence, the 1:100 dilution was chosen for this antibody rather than the 1:50 due 
to the amount of antibody available for the project. The antibody also had a staining 








Average rate of 
Transfection (%) 
24 HEK293T LTX with Plus NRASWT 38.7 
24 HEK293T LTX with Plus NRASMUT 38.6 
48 HEK293T LTX with Plus NRASWT 30.5 
48 HEK293T LTX with Plus NRASMUT 33.6 
30 HEK293T LTX with Plus NRASWT 39.4 
30 HEK293T LTX with Plus NRASMUT 40.2 
30 U87 3000 NRASWT 41.5 




Figure 3.8: Epifluorescent images from antibody optimisation. 
Dilutions/concentrations used in a titration experiment to determine the optimal amount of 
primary antibody organelle markers to use. Those chosen are in bold and underlined. 
*Dilution of GOLGA2 was subsequently altered to 1:500 
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3.4.3 HEK293T cells  
Localisation studies were initially performed in HEK293T cells as they are highly 
transfectable. These cells posed many issues including their semi adherent nature and 
their tendency to clump which resulted in the loss of many cells during the 
transfection and immunofluorescence staining process. The images obtained from 
these cells were also not of the desired quality. Cell clumping made imaging a single 
cell difficult and the close proximity of the cells made identifying organelle specific 
staining impossible as illustrated in Figure 3.9.a. Low levels of fluorescence and 
widespread background fluorescence lead to pixelated images and low resolving 
power. To overcome these issues a number of different concentrations of cells on 
coated and uncoated cover slips were used, as well as careful washing during the 
transfection and immunofluorescence processes (Sections 2.3 and 2.4.2). Background 
fluorescence was minimised during imaging through the use of the imaging 
parameters by increasing the offset and decreasing the gain (Section 2.4.6). Despite 
these attempts the images acquired were of insufficient quality to properly decipher 
specifically where the protein was localising. These images did however show a 
staining pattern similar to that seen in U87-MG cells which were used for all 




Figure 3.9: Confocal images of HEK293T cells. 
These cells are transfected with GFP2 tagged constructs and stained with a) PDI 
(endoplasmic reticulum marker), and b)  GM130/GOLGA2 (Golgi apparatus marker)  
 
Given the quality issues described above when using HEK293T cells the alternative 
U87-MG cell type was selected for ongoing transfection studies. As well as the quality 
issues with HEK293T there is an additional reason for selecting an alternative cell type, 
while NRAS is known to be expressed in most tissues48 and is likely to have an active 
role in cell survival growth and apoptosis in these, there are no documented patient 
symptoms that affect the kidney directly. To take account of this, U87-MG cells were 
also used. While this cell line has recently been discovered not to derive from the cell 
line originally described they are human glioblastoma cells94 and thus provides a 
different cell type in which to study the effects of the mutation.  
 
3.5 Localisation of NRASWT and NRASMUT  
The localisation of NRASWT and NRASMUT was studied to determine if the mutation 
resulted in altered localisation of NRAS and thus be closer to explaining the role of this 
mutation in the patient’s disease. The NRASWT and NRASMUT inserts were designed to 
be sub-cloned into two vectors to provide either the GFP2 or 3xFLAG tag as described 
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in section 2.1. The GFP2 tag allows the protein to be easily identified using fluorescent 
microscopy or flow cytometry, and thus allows the proteins location to be easily 
determined. However, the GFP2 protein is large and could affect the localisation of 
NRAS. As a control to check that this was not the case, the constructs were also 
tagged with the smaller 3xFLAG tag which was less likely to alter the protein 
localisation. Since the 3xFLAG tag does not fluoresce, an anti-flag antibody conjugated 
with a fluorescent tag was used to visualise the transfected protein. Cells were also 
labelled with organelle markers to determine whether the transfected proteins co-
localise with specific organelles.  
 
Markers for the plasma membrane (Glut1), for the Golgi apparatus (GM130/GOLGA2) 
and for the trans-Golgi network (TGN38) were selected as strong candidates for co-
localisation with NRAS based on the known localisation of NRAS. The results of the 
bioinformatic studies suggested that NRAS could also be targeted the mitochondria, 
ER and vesicles of the secretory system therefore several additional markers; PDI, 
EEA1, MitoTracker® orange and LAMP1, which stain the endoplasmic reticulum, early 
endosomes, mitochondria and lysosomes, respectively, were selected to be used. The 
Glut1 marker did not display staining specific to the plasma membrane as expected, 
instead showing strong cytoplasmic staining (Figure 3.10). Therefore, an additional 
plasma membrane marker (PMCA) was selected, as seen in Figure 3.10.b this marker 
showed the expected membrane specific staining pattern. Due to the inaccuracy of 




Figure 3.10: Comparison of the staining pattern of a) GLUT1 and b) PMCA. 
Both of these antibodies are plasma membrane markers however Glut1 appears to have a 
cytoplasmic staining pattern (a) as opposed to the expected membrane specific staining as 
seen in b) 
 
U87-MG Cells transfected with the pTagGFP2-N vector were used as a control for the 
localisation of the GFP2 tagged NRAS proteins. This was to confirm that the GFP2 tag 
was not altering the localisation of the NRAS proteins due to its large size. As 
presented in Figure 3.11 the GFP2 protein appears to localise throughout the cell, 
though there is an area of condensed localisation to the nucleus. Other controls 
included a; no primary antibody control for non-specific binding of the secondary 
antibodies, no secondary antibody control for auto fluorescence of the primary 
antibodies, no antibody control for cell auto-fluorescence and a no-DNA transfection 




Figure 3.11: Confocal image of U87-MG cells transfected with pTagGFP2-N vector. 
This was used as a control for the localisation of the GFP2 tagged NRAS proteins. The GFP2 
protein appears to be localising throughout the cell. 
 
Cells transfected with constructs and stained with organelle markers were visualised 
using confocal microscopy to take an image at a single point within the cell and thus 
determine if there was any co-localisation of the NRAS proteins with the markers 
used. In each of the results figures to follow, a series of four is presented: the nucleus 
stained with DAPI (blue), NRAS (green), the organelle of interest (red) and an overlay 




3.5.1 Golgi apparatus 
NRAS has been observed to be constitutively active on the Golgi apparatus51,53 and is 
known to travel bi-directionally between the plasma membrane and Golgi 
apparatus.49 Cells transfected with either the GFP2 tagged (Figure 3.12.a) or the 
3xFLAG tagged constructs (Figure 3.12.b) and stained with GM130/GOLGA2 show no 
evidence of localisation of NRASWT to the Golgi apparatus. There does however appear 
to be co-localisation of NRASMUT-GFP2 with GOLGA2 as indicated by the arrow in 
Figure 3.12.a. This staining pattern is not replicated with the 3xFLAG tagged construct 




Figure 3.12: GM130/GOLGA2 (Golgi apparatus marker) stained U87-MG cells 
Transfected with a) GFP2 and b).3xFLAG NRASWT and NRASMUT constructs. There appears to be co-localisation between NRASMUT-GFP 
and GOLGA2 indicated by the white arrow. There is no evidence of co-localisation in the remaining images. Scale bars are 10µm 
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3.5.2 Plasma membrane  
The plasma membrane was another location that NRAS has been observed to localise 
to.30 NRAS has been shown to be transiently active at the plasma membrane.51,53 
Results presented here (Figure 3.13.a) show that neither the wild type nor the mutant 
protein appear to be solely localising to the plasma membrane. There is no evidence 
that there is any co-localisation between PMCA and NRASWT, However there does 
appear to be partial co-localisation between PMCA and NRASMUT (Figure 3.13.a) 
 
3.5.3 Mitochondria 
NRAS has been observed on both the inner and outer membranes of the 
mitochondria.34,86 Therefore it was hypothesised that, if this localisation was disrupted 
in the mutant, it could lead to altered function of NRAS. No evidence was found for 
co-localisation of either the wild type or the mutant protein with the mitochondrial 





Figure 3.13: U87-MG Cells stained with a) PMCA (plasma membrane marker) and b) MitoTracker® Orange (mitochondria marker). 
The arrow highlights an area of co-localisation between NRASMUT and PMCA. There is no evidence of co-localisation between 
NRASWT and PMCA nor either construct with MitoTracker®. Scale bars are 10µm 
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3.5.4 Trans-Golgi network  
NRAS was found to be one of a number of proteins that were transported from the 
trans-Golgi network to the cell surface.50 To determine if the mutation disrupts this 
transport, cells stained with TGN38 were visualised. This antibody also showed non-
specific binding and high background levels even after optimisation (Figure 3.14.a). 
While neither protein appears to co-localise with the TGN38, the marker itself does 
not show the expected localisation.  Hence, firm conclusions cannot be drawn from 
the use of this marker.  
 
3.5.5 Endoplasmic Reticulum 
NRAS has been observed on the endoplasmic reticulum.50,51 This organelle was of 
particular interest as the endoplasmic reticulum is involved in folding and transport of 
proteins. If the mutation caused the disruption of localisation signals it could be 
retained by the endoplasmic reticulum for degradation. Results presented here show 
no evidence of co-localisation between NRASWT and the endoplasmic reticulum 
marker PDI (Figure 3.14.b). There does, however, appear to be partial co-localisation 
between NRASMUT and PDI as evident by the orange staining seen in the merged image 




Figure 3.14: U87-MG Cells stained with a) TGN38 (trans-Golgi network marker) and b) PDI (endoplasmic reticulum marker). 
The TGN38 antibody shows a staining pattern which is more cytoplasmic and less vesicular than expected. There is no evidence of co-
localisation between either construct with TGN38. There appears to be partial co-localisation between NRASMUT and PDI however there is 
no ER localisation seen in wild type transfected cells. An example of strong nuclear localisation is indicated by arrows. Scale bars are 
10µm 
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3.5.6 Lysosomes and Early endosomes 
The bioinformatic tool LocSigDB predicted that there was a lysosome localisation 
signal within the NRAS sequence (Section 3.2.2.2). In addition to this the lysosomes 
and early endosomes are involved in the recycling and transportation of proteins from 
and to the Golgi apparatus, trans-Golgi network and plasma membrane.95,96 Results 
obtained here (Figure 3.15) show no evidence of co-localisation of NRASWT or NRASMUT 




A number of tool including cNLS Mapper and PSORTII indicated that there was the 
potential for the NRAS proteins to localise to the nucleus (Section 3.2.2.1). All cells 
were stained with the nuclear stain DAPI which allowed for the localisation of NRAS to 
the nucleus to be observed. There was a large amount of variability in the localisation 
of the NRAS proteins to the nucleus as seen in Figures 3.12-3.15, however NRASMUT 
was consistently observed to co-localise with DAPI. An example of this localisation is 
highlighted with arrows in Figure 3.14.b. Nuclear localisation was rarely seen in cells 






Figure 3.15: U87-MG cells stained with a) LAMP1 (lysosome marker) and b) EEA1 (early endosome marker). 
Neither protein shows evidence of co-localisation with these markers. Scale bars are 10µm 
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3.6 Functional studies: 
3.6.1 Apoptosis assay 
An Andy Fluor 594 conjugated Annexin V product was used to detect and quantify the 
levels of apoptosis. Annexin V is one of a family of phospholipid binding proteins 
which have a high affinity for phosphatidylserine (PS).97 PS, which is located on the 
inner side of the plasma membrane in healthy cells, is translocated to the extracellular 
portions of the membrane during apoptosis.97 Therefore through the use of 
fluorescently labelled Annexin V paired with a cell viability stain, to discount those 
cells which are dead, apoptosing cells were detected and quantified using flow 
cytometry.  
 
The gating strategy for the apoptosis assay is shown in Figure 3.16. This was achieved 
by selecting the population of interest from a no-DNA control sample (Section 2.6.1) 
as shown in Figure 3.16.a, this forms population 1(P1). From P1 the populations of 
transfected and untransfected cells were selected (Figure 3.16.b). Transfected cells 
from the test population, untransfected cells acted as an internal control. As shown in 
Figure 3.16.c two samples of untransfected cells one stained with the LIVE/DEAD stain 
alone the other with  Annexin V alone were used to choose the appropriate gating. In 
addition to these the following positive controls were used: fixed/dead cells (data not 
shown) and cells in which apoptosis had been induced though incubation with sodium 
azide (data not shown). Figure 3.16.c shows that there are a small proportion of cells 
in an untransfected population that are dead or apoptosing as illustrated by the cell 




Figure 3.16: Gating strategy and controls for the Annexin V apoptosis assay. 
 a) Shows the selection of cells to form P1 using an untransfected population. b). shows the 
gating of transfected (green) and untransfected (blue) cells from population 1 using the 
untransfected population as the bench mark to select untransfected cells. c) Shows gating of P2 
using a quadrant to select those cells that are apoptosing (Q1-3), live (Q3-3), and dead (Q2-
3&4-3). The same quadrant was used for population 3 as well (data not shown). 
 
The results presented in Table 3.3 show that after transfection with the NRASWT or 
NRASMUT GFP2 constructs, there is a marginal increase in the percentage of apoptosing 
cells between the transfected and untransfected populations. This increase in 
apoptosis was observed in both wild type and mutant samples. However the increase 
is greater in cells transfected with the NRASMUT-GFP2 construct, with an increase of 
2.42 and 1.14 for replicate samples 1 and 2 respectively. In contrast the increase in 
wild type samples were a lower 0.38 and 0.95 for samples 1 and 2 respectively (Table 
3.3). There was no evidence of an increase in the percentage of dead cells between 
the transfected populations in the wild type (1.65%) and mutant samples (1.69%). 
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Table 3.3: Results of an Annexin V apoptosis assay. 
This table presents the proportion of live, dead and apoptosing cells in the transfected 
and untransfected populations of each sample identified using flow cytometry. The 













Transfected 96.83 0.51 2.67 22713 
0.38 
Un-transfected 96.67 1.05 2.29 21957 
 




Transfected 94.63 1.14 4.23 22911 
0.95 
Un-transfected 94.90 1.82 3.28 22119 
 




Transfected 93.03 0.93 6.04 19315 
2.42 
Un-transfected 95.39 0.99 3.62 27049 
       NRASMUT 
Sample 2 
Transfected 94.95 0.76 4.29 19724 
1.14 
Un-transfected 95.98 0.87 3.15 25991 
 
3.6.2 Bioinformatic prediction of the effect of the mutation. 
Since little is known about the mutation and its potential effects on the function of 
NRAS, the sequences of the tagged NRASWT and NRASMUT proteins were analysed using 
the online tool MOTIF search (http://www.genome.jp/tools/motif/). This tool 
annotates query amino acid sequences with predicted binding domains and functional 
motifs using several available databases; the Pfam database83 was used in this 
analysis. The result of this analysis is shown in Figure 3.17. The MOTIF tool predicted 
that the NRASWT-GFP and NRASMUT-GFP sequences contained both the RAS and GFP2 
motifs, as expected. As seen in Figure 3.17 the tool also identified the similarities 
between the input sequence and the RAS of complex (ROC) domain, 50S ribosome-
binding GTPase (MMR_HSR1) and ADP Ribosylation Factors (ARF). These are known to 
share sequence similarities as they are all in or associated with the RAS superfamily. 
This confirms that the tool is accurately identifying similar sequences 
 
The tool further identified similarities to a GTP_EFTU motif, indicated by an arrow in 
Figure 3.17, in both the wild type and mutant sequences. GTP_EFTU is the GTP binding 
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domain of elongation factor-thermo unstable (EF-Tu), which is highly conserved across 
all guanine nucleotide-binding proteins (G proteins), including the RAS proteins. The 
mutation site is located within this motif as shown by a red arrow in Figure 3.17. The 
independent E-values, calculated by MOTIF, confirm that the substitution of the 58th 
amino acid reduces the confidence of this prediction 10-fold; from 5.8e-05 for NRASWT 
to 6.7e-04 for NRASMUT. The same motifs, excluding GFP, were also identified in the 
3xFLAG tagged protein sequences (data not shown). 
 





GFP 212…432 Green fluorescent protein 7.1e-76 7.1e-76 
RAS 5…164 Ras family 8.3e-57 2.6e-55 
ROC 5…120 
Ras of complex, ROC, domain of 
DAPkinase 
4.8e-20 1.5e-19 
ARF 3…162 ADP-ribosylation factor family 7.4e-08 1.1e-08 
GTP_EFTU 47…160 
Elongation factor Tu GTP binding 
domain 
5.8e-05 0.00067 
DUF258 105…154 Protein of unknown function 0.095 0.089 
MMR_HSR1 6…117 50S ribosome-binding GTPase 0.00089 0.0026 
FeoB_N 108…154 Ferrous iron transport protein B 0.061 0.059 
     
Figure 3.17: Result from MOTIF search using Pfam database. 
The GFP2 tagged protein sequences were annotated with known motifs and functional domains. 
Both the wild type and mutant show the same motifs, with the tool correctly identifying both the 
RAS and GFP2 sequences. Of particular interest is the GTP_EFTU motif which is indicated with a 
black arrow. The approximate location of the mutation site is indicated with a red arrow. 
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The same sequences were also analysed using the CD-Search tool84 which searches 
the conserved domains database84 and annotates the input sequence with known 
protein domains. From this analysis it was found that the mutation site, highlighted by 
a red arrow in Figure 3.18, is predicted to be situated within a number of the 
conserved domains annotated in the sequence. These include a GEF interaction sight, 
G3 box which is an effector interaction site and GTP/Mg2+ binding site (Figure 3.18). 
The mutation is also adjacent to the Switch II region which is known to be involved in 
the change in conformation in response to GTP binding which allows NRAS to interact 




Figure 3.18: Annotated sequence for a) the NRASWT and b) the NRASMUT protein sequences using CD search  
There are a number of domains within the NRAS sequence which could be affected by the T58I mutation (red arrow) including a GEF interaction sight, G3box and 
GTP/MG2+ binding site.  
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3.7 Summary 
This study aimed to determine if the localisation and/or function of NRAS was effected 
by a novel c.173C>T (p.T58I) mutation identified in a patient with Noonan-like 
syndrome. A combination of bioinformatic analyses and literature searches predicted 
that the NRAS constructs could localise to a number of sub-cellular locations including 
the plasma membrane, endoplasmic reticulum, nucleus and secretory vesicles. These 
findings directed localisation studies, which were performed in U87-MG cells 
transfected with the GFP2 tagged NRASWT and NRASMUT constructs, to look for co-
localisation with markers for the; plasma membrane, Golgi apparatus, endoplasmic 
reticulum, lysosomes, early endosomes and mitochondria. This study identified 
localisation of the mutant protein to the Golgi apparatus, plasma membrane and 
endoplasmic reticulum, while wild type protein was not observed to co-localise with 
any of the markers used.  
 
An apoptosis assay was used to determine if the mutation resulted in an imbalance of 
the pro-survival/pro-apoptosis pathways as hypothesised to do. This assay identified 
an increase in the percentage of apoptosing cells in NASMUT transfected samples in 
comparison to both the wild type and an internal control of untransfected cells. 
Further functional analysis was performed using the bioinformatics tools MOTIF 
search and CD search which annotate protein sequences with known functional motifs 
and binding domains based on the Pfam and conserved domains database 
respectively. These tools identified that the mutation is located within/near a number 
of motifs including a GEF interaction sight, G3 effector interaction site, Switch II 
region, GTP/Mg2+ binding site and the GTP binding domain of EF-Tu, all of which are 
involved in the activation and/or inactivation of proteins.  
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4 DISCUSSION 
As outlined in the introduction to this thesis, the patient in this study was diagnosed 
with Noonan-like syndrome based on a number of phenotypic traits including gross 
motor delay, craniofacial anomalies: macrocephaly, high forehead, lowset ears 
hypertelorism, strabismus and palpebral ptosis and musculoskeletal abnormalities: 
webbed neck, pectus excavatum and hyper-extensible joints. This patient was not 
found to harbour mutations in any of the genes usually associated with Noonan 
syndrome such as PTPN11, KRAS and SOS1. However a novel mutation in NRAS was 
identified. NRAS is one of the three isoforms of RAS which work as molecular switches 
for signalling pathways31,32 thus playing a role in the regulation of cell growth, 
migration, survival, apoptosis and endocytosis.33 NRAS achieves this through its 
intrinsic GTPase activity by cycling between its inactive GDP-bound and active GTP-
bound states.34  
 
This potentially disease causing variant is a single nucleotide substitution (c.173C>T) in 
the 3rd exon of NRAS causing a substitution missense (p.Thr58Ile) mutation in NRAS. 
As this specific mutation has not been previously identified as a cause of Noonan 
syndrome this study aimed to validate its potential role in disrupting vital cell 
functions. The aim of this study was to identify bioinformatic and/or experimental 
evidence to suggest that the mutation results in disruption of localisation, and/or 
function, of NRAS. In doing so this study aimed to contribute to a lab-based pipeline 
which can be adapted for the validation of any rare disease variant discovered in 
Western Australian patients. 
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4.1 Localisation studies: 
The RAS proteins have a fairly wide distribution within a cell having been observed to 
localise to the: Golgi apparatus,50,51,85 plasma membrane,30 endoplasmic reticulum50,51 
and the inner and outer membranes of the mitochondria.34,86 This localisation has also 
been associated with their activation, a study by Chui et al (2002) showed that RAS 
stimulated with a growth factor is transiently active on the plasma membrane while it 
is constitutively active on the Golgi apparatus.51 Given that this mutation was found to 
be an activating mutation (M. Tartaglia and G. Baynam, personal communication, 
2016), it was hypothesised that the mutation would result in the localisation of 
NRASMUT to the Golgi apparatus more so than the plasma membrane. While the 
results presented here suggest there was co-localisation between the mutant and the 
Golgi apparatus marker there was also co-localisation with the plasma membrane, 
suggesting that the activation of NRAS caused by the mutation is not the only factor 
affecting its localisation. While the localisation studies performed were qualitative, 
using intensity scatter plots, a quantitative analysis of localisation would be possible. 
An intensity scatter plot, as the name suggests, plots the intensity of each pixel of one 
colour against each pixel of a second98, in this case the red of a marker and the green 
of NRAS. A quantitative analysis of localisation would allow for an increase, or 
decrease, in the co-localisation of NRASMUT with these markers, in comparison to 
NRASWT, to be determined.  
 
The activation of RAS on the Golgi apparatus is still not fully understood. Two current 
hypotheses suggest that the activation is the result of retrograde transport of RAS 
from the plasma membrane or that RAS relies on diffusible mediators which transfer 
messages from the plasma membrane to the Golgi apparatus which determine the 
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activation of RAS.33 Current experimental data33,85 indicates that the second 
hypothesis is likely. These data suggests that calcium is the mediator, causing an 
increase in calcium dependant exchange factors to the Golgi apparatus and GAPs to 
the plasma membrane, leading to activation of RAS at the Golgi apparatus and 
inactivation at the plasma membrane.33,85 If this process is disrupted by the mutation 
resulting in active NRAS at both locations, or in incomplete activation at the plasma 
membrane this would explain the gain-in-function resulting from this mutation. To 
test this hypothesis the interaction of NRAS with effector molecules could be studied 
using a gel based pull-down assay. This would allow for the interaction of NRAS with 
the proteins known to be involved in the activation and inactivation, such as GEF and 
GAPs, to be studied (Section 4.2). If the mutation is causing NRAS to interact with 
these protein more or less than normal this would likely lead to a disruption of this 
activation/inactivation cycle.  
 
Localisation of NRASMUT to both the plasma membrane and Golgi apparatus indicate 
that the mutant protein is functioning normally and is thus able to be shuttled 
bidirectionally between the Golgi apparatus and plasma membrane, as wild type NRAS 
has previously been shown to do.49 While this appears to be the natural subcellular 
localisation of NRAS, in the work carried out in this thesis the NRASWT protein showed 
no evidence of co-localisation with either of the markers for these subcellular 
compartments as would have been expected.  
 
NRASMUT also showed strong nuclear localisation. While weak nuclear localisation was 
predicted when analysing the insert sequences using the online tools cNLS mapper 
and PSORTII, it was predicted for both the wild type and mutant proteins. There is no 
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evidence to suggest that the mutation would result in nuclear localisation. In addition 
if this localisation pattern were caused by the addition of the GFP2 tag there is no 
explanation as to why nuclear localisation was consistently seen in NRASMUT 
transfected cells but not in NRASWT transfected cells. Further evaluation of the 
3xFLAG-tagged constructs could identify if this nuclear localisation is NRAS-GFP2 
specific. To come to any conclusion further studies using smaller tags or completely 
untagged NRASMUT and NRASWT proteins, would be required. The latter would require 
the use of an antibody marker to the NRAS protein itself, followed by a fluorescent-
tagged secondary antibody layer for visualisation. 
 
In addition to nuclear localisation, NRASMUT displayed partial co-localisation with PDI; 
an endoplasmic reticulum marker. This result was not seen in all images taken and 
thus further studies would be required to make any firm conclusions about 
endoplasmic reticulum localisation. If NRASMUT is localising to the endoplasmic 
reticulum this may be because it is getting stuck during the post-translational process 
as the endoplasmic reticulum is one of the intermediate localisations prior too binding 
with the Golgi apparatus. There is no evidence to suggest that NRAS is retained in the 
endoplasmic reticulum, both the wild type and mutant sequences lack specific 
endoplasmic reticulum retention signals like KDEL99 and neither the 3xFLAG nor GFP2 
tag introduces one. 
 
The lack of co-localisation of NRASWT with any of the markers used, despite the fact 
that NRAS has been observed at many of these locations, suggests that the 
localisation or activation of the wild type protein is disrupted by the addition of the 
GFP2 tag. When looking at images taken of cells transfected with the pTagGFP2-N 
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vector alone, there are similarities between the staining pattern of GFP2 and NRASWT. 
This could be caused by the GFP2 tag altering the localisation of NRASWT due to the 
size of the tag, however, there is no reason why only the wild type protein would be 
affected and not the mutant protein. The second possibility is that the NRASWT insert 
was lost during the process of bulking up the plasmid in bacteria and its subsequent 
extraction, resulting in expression of GFP2 only. The third possibility is that NRASWT is 
truly localising to the cytoplasm. These three possibilities are discussed further below. 
 
The first point was addressed through the use of cells transfected with 3xFLAG tagged 
constructs. 3xFLAG is a smaller less obtrusive tag that is well known and frequently 
used for tagging of proteins. Both NRASWT-3xFLAG and NRASMUT-3xFLAG show a 
similar pattern of localisation as they do when tagged with the GFP2 tag. However, 
the 3xFLAG images were not of sufficient quality to make a definite conclusion. This 
suggests that the GFP2 tag is not altering the localisation of the protein. This 
suggestion is supported by the results of a study performed by Choy et al (1999) in 
which the localisation of endogenous RAS was used to confirm that their GFP-RAS 
construct was not localising unnaturally.50 It is possible, however, that both the GFP2 
and 3xFLAG tags lead to mislocalisation of NRAS. If this is the case overcoming this 
would require the use of cells which expressed only the wild type or mutant NRAS 
form, such as patient derived cell lines.  
 
The second possibility was addressed through restriction digest of the plasmid DNA 
which confirmed that both the NRASWT and NRASMUT inserts were present in the 
plasmid DNA extracted from transformed bacteria and that they were of the expected 
size. This was further supported by a western blot of protein extracted from 
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transfected cells which showed that the NRAS-GFP2 protein was expressed in both the 
wild type and mutant samples, that they were of the expected size and that there was 
significant difference in size to that of GFP2 alone.  
 
Thirdly the cytoplasmic staining pattern observed could be the result of NRASWT, and 
NRASMUT, being unable to bind strongly to its intended target, this is supported by a 
study which showed that the anchorage of RAS to the membrane is relatively weak.52 
Therefore it is possible that the addition of tags further reduces the efficiency of NRAS 
to bind to the membrane. Alternatively NRASWT may naturally be localising to the 
cytoplasm, as the transport of depalmitoylated RAS from the plasma membrane to the 
Golgi apparatus has been shown to involve a cytosolic intermediate.100 
 
4.2 Functional studies: 
Preliminary analysis of the novel p.T58I substitution identified it to be a gain-of-
function mutation that results in the enhanced expression of the ERK and AKT 
proteins (M. Tartaglia and G. Baynam, personal communication, 2016). AKT has a 
major role in regulating cell survival87 and an increase in active AKT has been shown to 
protect a number of cell lines, including COS-788 and MDCK89 epithelial cells, from 
apoptosis induced in a number of ways. Therefore, it was hypothesised that an 
increase in AKT caused by the mutation would result in lower levels of apoptosis. The 
results of this study are directly conflicting with this hypothesis as there was an 
increase in apoptosis observed in cells transfected with NRASMUT. This may be the 
result of a pro-apoptotic response from RAS to an increased activation of the RAS–
RAF–MAPKK–MAPK pathway. This has been identified as one of the triggers causing 
RAS; which normally has a pro-survival function, to promote apoptotis.101,102 While 
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there is no evidence as yet to suggest that the mutation affects the activation of the 
whole RAF–MAPKK–MAPK pathway, the mutation is known to cause the increased 
expression of ERK, also known as MAPK.  
 
Due to the small sample size used in the apoptosis assay the statistical significance of 
the increase in apoptosis was unable to be determined. Only a single experiment with 
duplicates of each sample was performed, therefore definitive conclusions cannot be 
made from this data. This study was not repeated due to time constraints. Further 
replication of this assay needs to be performed in cells which do not contain the 
endogenous copy, for example in cells in which the gene is knocked-down, or using 
patient derived cell lines. This is because it is ambiguous as to whether the effect seen 
is due to an over expression of NRAS, and it is likely that any effects of NRASMUT are 
masked by the endogenous copy. 
 
Due to the limited time to generate experimental evidence for change of function, 
additional bioinformatic analyses were undertaken to predict putative effects of the 
mutation on protein function. The bioinformatics tool MOTIF showed that the 
mutation was found within a region which is similar to the conserved GTP_EFTU 
domain. GTP_EFTU is the GTP binding domain of the EF-Tu which is a G-protein that 
works in a similar way to the RAS proteins by cycling between its inactive GDP bound 
and active GTP bound states.103 The binding of GTP to EF-Tu occurs in this domain, 
which is highly conserved across all G-proteins.103 There are four main motifs within 
this binding domain, the second of which is a DxxG sequence. In RAS this sequence is 
DTAG and spans the 57th-60th amino acids103 indicating that a T58I mutation could 
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disrupt this motif. The disruption of this motif could result in the disruption of the 
GTPase activity of NRAS. 
 
The second tool used supported these findings, this tool, CD-Search, identified that 
the mutation sits within/near a number of conserved domains. These include a GEF 
interaction site, a G3 box; an effector interaction site, and a GTP/Mg2+ binding site. All 
three of these domains are involved in the activation and inactivation of NRAS. The 
importance of the 58th amino acid in these regions is unknown however it is possible 
that this is the cause of the gain-of-function that results from the mutation.  
 
The mutation is also adjacent to the Switch II region which is known to be involved in 
the change in conformation in response to GTP binding which allows NRAS to interact 
with effector proteins and activate them.20,45 Mutations identified within or near the 
switch II region have previously been shown to interfere with the GTPase function of 
RAS.17 Therefore, if the efficiency of Switch II is affected by this mutation, it would 
likely lead to NRAS being stuck in its inactive or active state. This in turn would lead to 
more or less interaction with effector proteins, leading to the disruption of 
downstream cellular activity. Since this mutation is known to be a gain-of-function 
mutation it is likely that if this Switch II region is affected it would result in the protein 
being stuck in the active conformation. 
 
4.3 Experimental validation pipeline: 
Although this study failed to provide definitive data to validate the role of this novel 
NRAS mutation in causing Noonan-like syndrome, it was successful in providing 
information that can contribute to the development of a pipeline for the validation of 
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other novel rare disease variants. In particular this study highlights the areas of the 
pipeline which need to be altered or extended to obtain more conclusive results.  
 
Optimisation of the experimental pipeline was a large part of this study. The 
optimisations and quality controls performed in this study as described in sections 
2.1.1, 2.1.2, 2.1.4, 2.3.1 and 2.4.2.1 are necessary for any variants studied with this 
pipeline. Antibody marker optimisation, in particular, allowed for the inefficiency of 
the Glut1 antibody to be identified. The nonspecific staining of Glut1 seen in this study 
may be related to the use of it in association with RAS, as RAS has been associated 
with an increased transcription of Glut1 in order for increased glucose uptake.104 
Therefore it is possible that, in transfected cells which have an over expression of 
NRAS, there is also an overabundance of Glut1. In addition to this it was further 
discovered that U87-MG cells have low levels of membrane bound Glut1,105 making 
Glut1 the wrong antibody to use in this particular cell type.  
 
The pipeline used in this study involved designing gene inserts to be sub-cloned into 
both the GFP2 and 3xFLAG tagged expression vectors. Due to the size of the GFP2 tag 
the results gained with GFP2 tagged constructs needs to be validated if any anomalies 
are seen. This could be overcome with the use of patient derived cell lines in which 
NRAS could be directly probed.  
 
In order to perform the functional analyses needed to determine the effects of a 
mutation on protein function the pipeline needs in include the creation of stably 
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transfected cells. This was one of the main limitations of this study as the transfected 
cells used were transiently transfected, thus the plasmid was episomal and lost during 
replication making longer-term assays impossible. Using stably transfected cells would 
allow for long-term analysis such as a proliferation or protein interaction assays to be 
performed. In addition to stably transfected cells, to successfully study the function of 
the mutant protein, the endogenous copy needs to be under expressed or absent 
from the cells. Using patient derived cell line would allow this to be done in a more 
efficient fashion and would make the designing of construct unnecessary, thus 
removing the ambiguity revolving around the addition of tags to NRAS. 
 
Two examples of simplified validation pipelines that could result in less ambiguous 
results are shown in Figure 4.1. Figure 4.1.a shows a pipeline which utilises the same 
construct design, bioinformatic analyses and transfection process as this study, with 
the addition of stable transfection cells to allow for further functional studies to be 
performed. Figure 4.1.b shows an ideal pipeline which uses patient derived cell lines 
for functional and localisation studies. This would remove the need for the GFP2 and 





Figure 4.1: Two simplified experimental pipelines for the validation of rare disease 
variants. 
a) Shows a pipeline which utilises the same construct design as used in this study with 
the addition of stably transfected cells to allow for further functional studies to be 
performed. b) Shows an ideal pipeline which uses patient derived cell line for functional 
and localisation studies. 
 
4.4 Conclusion and further studies 
In conclusion the results of this study are insufficient to validate the role of the 
c.173C>T p.T58I substitution in the rare disease Noonan-like syndrome. The 
preliminary information from this study indicates a potential difference in localisation 
and function between the mutant and wild type proteins. The mutant protein was 
seen to co-localise with the Golgi apparatus as expected if the mutant protein was 
constitutively active. However the mutant protein was also observed to co-localise 










































could indicate that the mutation affects more than just the activation of the protein. 
The wild type protein however was not seen to co-localise with any of the markers 
used leading to questions as to the validity of these results. 
 
The functional assays performed, while limited to studies in transiently rather than 
stably transfected cells, indicate an increase in apoptosis in cells containing the 
mutant protein. This is the opposite of expected. These results however are 
preliminary and further replicates need to be performed to determine the significance 
of this difference before any conclusions are made. Bioinformatic analysis of the insert 
sequences revealed that the mutation is likely to affect the binding of GTP and/or the 
change in conformation associated with this binding. This is in line with the 
preliminary finding on the same mutation which showed that the mutation results in a 
gain in function.  
 
To fully understand the effect of this mutation and thus validate its role in Noonan, 
further study is required. In particular further functional analyses in stably transfected 
cells looking at the: proliferation and differentiation of cells containing the mutant 
protein, activation of NRAS and interaction of NRAS with other proteins such as the 
GEF and GAPs. These functions are of particular interest as ERK and AKT, which are 
known to have enhanced expression caused by this mutation, are known to have a 
role in the regulation of apoptosis, cell proliferation and differentiation.87,101,102,106 In 
addition bioinformatic analysis in this study identified that the mutation was found 
within/near a number of motifs involved in GTP binding and the interaction GTP 
bound NRAS with effector molecules. 
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Ideally functional and localisation studies would also be repeated in patient derived 
cell line. For the localisation studied this would remove the ambiguity of the GFP2 and 
3xFLAG tags and their effects on the localisation of the NRAS. This would also enable 
the results of functional assays to be less ambiguous as the endogenous wild type 
NRAS expressed in the cell lines used in this study would be under expressed.  
 
An alternate way to achieve this is to using CRISPR/Cas (clustered regularly 
interspaced short palindromic repeats/CRISPR-associated protein) system. This system 
is derived from the adaptive immune system used by the many bacteria and archaea 
to protect against the invasion of nucleic acids, for example during viral infection.107-
109 When transcribed the CRISPR sequences act as guide RNA which identify foreign 
DNA and target it for inactivation by nuclease-mediated cleavage.110 One of the more 
commonly used systems is CRISPR/Cas9 which was adapted from Streptococcus 
pyogenes and optimised for genome editing in vertebrate cells.110-113 Using this system 
would allow for two cell lines to be produced that are identical other than the NRAS 
mutation of interest. This would also, in theory, allow for the mutation in patient 
derived cell line to be repaired and return to normal function proving the effects of 
the mutation.  
 
The information gained from these additional studies would allow for the mutation to 
be properly validated and in combination with the information gained in this study 
provided the information needed to develop a more efficient pipeline to perform 
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Appendix I: Full gene names used in thesis 
Official gene symbol Official gene name 
AKT AKT serine/threonine kinase 1 
BRAF B-Raf proto-oncogene, serine/threonine kinase 
CBL Cbl proto-oncogene 
ERK Extracellular regulated MAP kinase 
GRB2 Growth factor receptor bound protein 2 
HRAS V-HA-RAS Harvey rat sarcoma viral oncogene homolog 
KRAS V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog  
LZTR1 
 
Leucine-zipper-like transcription regulator 1 
MEK MAP kinase-ERK kinase 
NF1 Neurofibromin 1 
NORE1/ RASSF5 RAS association domain family member 5 
NRAS neuroblastoma RAS viral oncogene homolog 
PDK1 Phosphoinositide-dependent kinase 1 
PI3K Phosphatidylinositol 3-kinase 
PTPN11/ SHP2 Protein tyrosine phosphatase, non-receptor type 11 
RAF1/ CRAF Raf-1 proto-oncogene, serine/threonine kinase 
RAL RAS Like protein 
RalGDS Ral guanine nucleotide dissociation stimulator 
RASSF1 RAS association domain family member 1 
RIT1 RAS like without CAAX 1 
SHC/NF2 Neurofibromin 2 
SHOC2 SHOC2, leucine rich repeat scaffold protein 
SOS1 SOS RAS/Rac guanine nucleotide exchange factor 1 
SOS2 SOS RAS/Rho guanine nucleotide exchange factor 2 
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Appendix II: Full plasmid maps provided by Invitrogen GeneArt™, images generated 




Appendix III: Nucleotide sequences for the NRASWT and NRASMUT inserts with and 
without the GFP2 and 3xFLAg tags. These sequences were used to get the predicted 
protein sequences using ExPASy. 
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Appendix IV: Predicted amino acid sequences of tagged and untagged NRASWT and 









































Appendix V: Full results from LocSigDB 
NRASWT 
 
NRASWT-GFP 
 
NRASWT-3xFLAG 
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NRASMUT 
 
NRASMUT-GFP2 
 
NRASMUT-3xFLAG 
 
 
